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Abstract 
The epidemic of HIV I AIDS in the United States is constantly changing and evolving, 
starting from patient zero to now an estimated 650,000 to 900,000 Americans in-
fected. The nature and course of HIV changed dramatically with the introduction of 
antiretrovirals. This discourse examines many different facets of HIV from the begin-
ning where there wasn't any treatment for HIV until the present era of highly active 
antiretroviral therapy (HAART). By utilizing statistical analysis of clinical data, this 
paper examines where we were, where we are and projections as to where treatment 
of HIV I AIDS is headed. 
Chapter Two describes the datasets that were used for the analyses. The pri-
mary database utilized was collected by myself from an outpatient HIV clinic. The 
data included dates from 1984 until the present. The second database was from the 
Multicenter AIDS Cohort Study (MACS) public dataset. The data from the MACS 
cover the time between 1984 and October 1992. Comparisons are made between both 
datasets. 
Chapter Three discusses where we were. Before the first anti-HIV drugs (called 
antiretrovirals) were approved, there was no treatment to slow the progression of HIV. 
The first generation of antiretrovirals, reverse transcriptase inhibitors such as AZT 
(zidovudine), DDI (didanosine), DDC (zalcitabine), and D4T (stavudine) provided 
the first treatment for HIV. The first clinical trials showed that these antiretrovirals 
had a significant impact on increasing patient survival. The trials also showed that pa-
tients on these drugs had increased CD4+ T cell counts. Chapter Three examines the 
distributions of CD4 T cell counts. The results show that the estimated distributions 
of CD4 T cell counts are distinctly non-Gaussian. Thus distributional assumptions 
regarding CD4 T cell counts must be taken into account when performing analyses 
with this marker. The results also show the estimated CD4 T cell distributions for 
each disease stage: asymptomatic, symptomatic and AIDS are non-Gaussian. In-
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terestingly, the distribution of CD4 T cell counts for the asymptomatic period is 
significantly below that of the CD4 T cell distribution for the uninfected population 
suggesting that even in patients with no outward symptoms of HIV infection, there 
exists high levels of immunosuppression. 
Chapter Four discusses where we are at present. HIV quickly grew resistant to 
reverse transcriptase inhibitors which were given sequentially as mono or dual therapy. 
As resistance grew, the positive effects of the reverse transcriptase inhibitors on CD4 
T cell counts and survival dissipated. As the old era faded a new era characterized 
by a new class of drugs and new technology changed the way that we treat HIV-
infected patients. Viral load assays were able to quantify the levels of HIV RNA in 
the blood. By quantifying the viral load, one now had a faster, more direct way to test 
antiretroviral regimen efficacy. Protease inhibitors, which attacked a different region 
of HIV than reverse transcriptase inhibitors, when used in combination with other 
antiretroviral agents were found to dramatically and significantly reduce the HIV 
RNA levels in the blood. Patients also experienced significant increases in CD4 T cell 
counts. For the first time in the epidemic, there was hope. It was hypothesized that 
with HAART, viral levels could be kept so low that the immune system as measured 
by CD4 T cell counts would be able to recover. If these viral levels could be kept 
low enough, it would be possible for the immune system to eradicate the virus. The 
hypothesis of immune reconstitution, that is bringing CD4 T cell counts up to levels 
seen in uninfected patients, is tested in Chapter Four. It was found that for these 
patients, there was not enough of a CD4 T cell increase to be consistent with the 
hypothesis of immune reconstitution. 
In Chapter Five, the effectiveness of long-term HAART is analyzed. Survival 
analysis was conducted on 213 patients on long-term HAART. The primary endpoint 
was presence of an AIDS defining illness. A high level of clinical failure, or progression 
to an endpoint, was found. 
Chapter Six yields insights into where we are going. New technology such as viral 
genotypic testing, that looks at the genetic structure of HIV and determines where 
mutations have occurred, has shown that HIV is capable of producing resistance mu-
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tations that confer multiple drug resistance. This section looks at resistance issues 
and speculates, ceterus parabis, where the state of HIV is going. This section first 
addresses viral genotype and the correlates of viral load and disease progression. A 
second analysis looks at patients who have failed their primary attempts at HAART 
and subsequent salvage therapy. It was found that salvage regimens, efforts to control 
viral replication through the administration of different combinations of antiretrovi-
rals, were not effective in 90 percent of the population in controlling viral replication. 
Thus, primary attempts at therapy offer the best change of viral suppression and 
delay of disease progression. Documentation of transmission of drug-resistant virus 
suggests that the public health crisis of HIV is far from over. Drug resistant HIV 
can sustain the epidemic and hamper our efforts to treat HIV infection. The data 
presented suggest that the decrease in the morbidity and mortality due to HIV I AIDS 
is transient. Deaths due to HIV will increase and public health officials must pre-
pare for this eventuality unless new treatments become available. These results also 
underscore the importance of the vaccine effort. 
The final chapter looks at the economic issues related to HIV. The direct and 
indirect costs of treating HIV I AIDS are very high. For the first time in the epidemic, 
there exists treatment that can actually slow disease progression. The direct costs 
for HAART are estimated. It is estimated that the direct lifetime costs for treating 
each HIV infected patient with HAART is between $353,000 to $598,000 depending 
on how long HAART prolongs life. If one looks at the incremental cost per year of 
life saved it is only $101,000. This is comparable with the incremental costs per year 
of life saved fror;n coronary artery bypass surgery. 
Policy makers need to be aware that although HAART can delay disease progres-
sion, it is not a cure and HIV is not over. The results presented here suggest that 
the decreases in the morbidity and mortality due to HIV are transient. Policymak-
ers need to be prepared for the eventual increase in AIDS incidence and mortality. 
Costs associated with HIV I AIDS are also projected to increase. The cost savings 
seen recently have been from the dramatic decreases in t he incidence of AIDS defin-
ing opportunistic infections . As patients who have been on HAART the longest start 
lX 
to progress to AIDS, policymakers and insurance companies will find that the cost of 
treating HIV /AIDS will increase. 
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Chapter 1 Introduction 
AIDS (acquired immune deficiency syndrome) was first reported by Michael Gottlieb 
in 1981 [1]. The virus that causes AIDS was first isolated by Barre-Sinoussi in 1983 [2] . 
Since then approximately 25 million people worldwide have been infected with HIV 
(human immunodeficiency virus). 
Before the advent of effective treatment for HIV I AIDS, the impact of HIV I AIDS 
on the United States health care system was large. It was estimated that the life-
time cost of treating each HIV-infected individual was $119,000 [3] (1993 dollars). 
According to the Centers for Disease Control (CDC), 650,000 to 900,000 Americans 
are living with HIV and at least 40,000 new infections occur each year [4]. 
Before zidovudine (AZT), the first antiretroviral, there was no treatment for HIV. 
It was estimated that the average time between seroconversion and diagnosis of an 
AIDS defining opportunistic infection was ten years [5]. Risk of contracting an op-
portunistic infection increased greatly once a patient's CD4 T cell counts went below 
200 cellslmm31 . Once a patient had a CD4 T cell count less than 200 cellslmm3 , 
median time until death was two years [6]. AIDS was becoming a public health crisis. 
There were too few hospital beds, too few doctors, and no treatment to give patients 
to slow the progression of the disease. 
The first anti-HIV drug zidovudine (AZT, retrovir) was first approved by the Food 
and Drug Adminstration (FDA) in 1986. AZT is part of a class of drugs called reverse 
transcriptase inhibitors (RTI). RTI's attack the enzyme that allows HIV to replicate, 
reverse transcriptase. The first clinical trial with AZT showed a marked increase 
in survival for patients that were on the AZT arm of the study [7]. Patients on 
AZT also experienced an increase in CD4 T cell counts. Similar results were found 
with other reverse transcriptase inhibitors. Viral load reductions with RTI's were 
1 CD4 T cells are a primary target of HIV. CD4 T cells are also an important component of the 
immune system. The normal range is 700-1400 cells/mm3 . 
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rapid but incomplete and viral rebound was found six to twelve months later. Viral 
rebound was due to the presence of resist ance conferring mutations in HIV reverse 
transcriptase [8, 9] . The improvements seen with RTI monotherapy were transient 
and patients experienced a resurgence in viral load , CD4 T cell decline and disease 
progression. 
Protease inhibitors (PI) were the next step forward in the fight against AIDS. 
Protease inhibit ors were different from reverse transcriptase inhibitors in that these 
drugs attacked a different target of the HIV replication cycle. Thus HIV that was 
resistant to RTI's would be susceptible to protease inhibitors. RTI's and PI's were 
used in combination, referred to as highly active antiretroviral therapy (HAART) , 
produced dramatic and sustained reductions in viral load. CD4 T cells increased sub-
stantially. CDC estimates of morbidity and mortality due to HIV infection decreased 
for the first time [4]. This result is attributed to the introduction of HAART [10] . 
For the first time in the epidemic, there was hope that HIV could be managed as a 
chronic disease. 
It was hypothesized that if viral levels could be kept low enough long enough that 
the immune system would be able to reconsitutute [11]. Immune reconstitution, that 
is bringing t he levels of CD4 T cell counts back up to levels similar to uninfected 
people, would reduce the risk of patients contracting an opportunistic infection. Fail-
ure to isolate infectious virus from PBMC (peripheral blood mononuclear cells) or 
lymphoid tissue from patients who had sustained viral suppression on HAART for 
two years [12] fueled speculation that HIV could be eradicated [13]. In recent studies, 
it was found that replication competent virus could be isolated from a latent reser-
voir [14, 15, 16] . T hese results suggest that at present, HIV is not eradicated by 
HAART. 
Chapter Two details the datasets that were used for the analyses. The primary 
dataset utilized was collected by myself from Dr. Michael Gottlieb's outpatient clinic. 
Outpatient clinics differ substantially from the controlled environment of a clinical 
t rial. To assess t he impact of HIV and its treatment on the more general patient 
population, it was necessary to obtain data from an outpatient clinic. Data were 
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collected between June 1995 and February 1999. Data were abstracted from patient 
charts and entered into a computer. Insurance information was then matched into 
the clinical database by a unique identification number. Care was taken to ensure 
patient privacy and anonymity. Diagnostic tests were run to ensure the accuracy 
of the data. Any discrepancies were remedied by checking the chart or consultation 
with the treating physician. Data were collected on biologic markers such as CD4 T 
cell counts and percentages, CD8 T cell counts and percentages, ratio of CD4 T cell 
counts to CD8 T cell counts, HIV-1 RNA levels (viral loads), /32 microglobulin levels, 
presence of p24 antigen, cholesterol, triglycerides, and weight. Data was also gathered 
on cost, insurance status, diagnosis, treatments, antiretroviral therapy, prophalaxis 
therapy, home health care, and hospitalizations. 
The second data set was obtained from the Multicenter AIDS Cohort Study 
(MACS) public data set. The MACS is described Kaslow et al. [17]. The MACS 
is a prevalence database that has both seropositive (HIV infected) and seronegative 
(HIV uninfected) in the study population. Data was gathered on CD4 T cell counts, 
CD8 T cell counts, physical examination findings, and survey questions on medica-
tions, diagnoses, and socio-economic questions. Data from the public data tape start 
in 1984 and end October 1992. 
Chapters Three describes where we were, no treatment to reverse transcriptase 
inhibitor dual or monotherapy. It was found that reverse transcriptase inhibitors in-
creased CD4 T cell counts. However, this effect was transient. It was also assumed 
that the distribution of CD4 T cell counts was Gaussian, regardless of the disease 
stage. A nonparametric density estimator was applied to the repeated CD4 T cell 
counts of patients on reverse transcriptase inhibitor mono or dual therapy. In section 
three it is shown that this methodology applied to repeated measures data is consis-
tent and unbiased. The analysis found that the estimated distribution of the CD4 T 
cell counts were not distributed Gaussian. It was also found that when the patients 
were segregated by disease stage: asymptomatic, symptomatic, and AIDS, the CD4 
T cell counts in all stages were distinctly non-Gaussian. In fact, in the AIDS stage 
the distribution is bimodal. In the asymptomatic period, there was a substantial 
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decrease in CD4 T cell counts when compared to the uninfected population. This 
suggests that patients who have no outward symptoms of HIV could have a high level 
of immunosuppression despite antiretroviral therapy. 
Chapters Four and Five detail where we are presently in the treatment of HIV 
infection. HIV quickly grew resistant to dual and mono therapy reverse transcriptase 
inhibitors. Protease inhibitors and combination antiretroviral therapy rapidly and 
significantly reduced the levels of circulating virus in HIV-infected patients. Increases 
in CD4 T cell counts and reductions in the morbidity and mortality due to HIV lead 
scientists to hypothesize about immune reconstitution and viral eradication. Two 
papers are presented in that address both of these hypotheses. Chapter Four looks 
at the CD4 T cell distribution of patients on highly active antiretroviral therapy 
(HAART). Using a nonparametric density estimator, it is found that the CD4 T 
cell increases due to HAART are insufficient to be consistent with the hypothesis of 
immune reconstitution. The paper also shows that the estimator is consistent and 
unbiased for repeated measures data. Chapter Five looks at the rate of clinical failure 
for patients on long- term HAART. Clinical failure is defined here as diagnosis with an 
opportunistic infection or a decrease of CD4 T cell counts to below 200 cells/mm3 . It 
was found that the median time until clinical failure was 586 days. Failure of HAART 
to eradicate the virus leaves patient vulnerable to viral resistance and resurgence. 
Chapter Six glimpses at the future of HIV treatments. A growing number of clin-
ical patients are experiencing virologic and clinical failure despite being on HAART. 
Virologic failure is defined as failure to keep the virus suppressed to very low levels 
in the peripheral blood and plasma. Clinical failure is defined as progression to an 
AIDS defining event. As more and more patients are failing t heir primary attempts 
at combination therapy, salvage therapy, defined as different combinations of drugs 
to which the patient is naive, has b ecome an important issue. Whether due to cross-
resistance or viral breakthrough, it was found that salvage therapy is not effective 
in producing a sustained virologic response in heavily pre-treated patients. Within 6 
months after the initiation of a salvage regimen, the majority of patients experience 
virologic failure . This disappointing result is due, for the most part, to drug resistant 
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virus. Viral genotyping has shown high level resistance in patients who fail salvage 
regimens. With the documented transmission of drug resistant strains of HIV, the 
scenario worsens. If the prevalence of resistant strains is high, t hen patients may 
be already resistant to antiretroviral medications. Because of cross-resistance, there 
might not exist an antiretroviral agent to which there would not be some form of 
resistance . 
Chapter Seven looks at the economic costs related to t he treatment of HIV. The 
direct and indirect costs of treating HIV I AIDS are very high. For the first time 
in the epidemic, there exists t reatment that can actually slow disease progression . 
The direct costs for HAART are estimated. It is estimated that t he direct lifetime 
costs for treating each HIV infected patient with HAART is between $546,668.78 
t o $723,069.20 depending on how long HAART prolongs life. If one looks at t he 
incremental cost per year of life saved it is only $150,948.84. This is comparable with 
the incremental costs per year of life saved from coronary artery bypass surgery. 
Policy makers need to be aware that alt hough HAART can delay disease progres-
sion, it is not a cure and HIV is not over. The results presented here suggest that 
the decreases in the morbidity and mortality due to HIV are transient. Policymak-
ers need to be prepared for the eventual increase in AIDS incidence and mortality. 
Costs associated with HIV I AIDS are also projected to increase. The cost savings 
seen recently have been from the dramatic decreases in the incidence of AIDS defin-
ing opportunistic infections. As patients who have been on HAART the longest start 
to progress to AIDS, policymakers and insurance companies will find that the cost of 
treating HIV I AIDS will increase. 
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Chapter 2 Data 
2.1 Outpatient Data 
The primary dataset used in the analyses was constructed from the retrospective 
chart review of 325 charts of HIV-infected patients from Dr. Michael Gottlieb's 
outpatient clinic. Data collection and follow up was performed continuously over 
the space of five years. Patients were selected by a 30 percent random sample of 
Gottlieb's patient base. The only selection criteria was seropositivity. No patients 
were excluded because of this criteria. As this was an intent to treat analysis, all 
variables were gathered on all patients regardless of treatment regimen. 
Data were collected by reading through patient charts and entering the data into 
Excel 5.0 on a laptop computer. Excel was chosen for its flexibility and ease into 
importing into a variety of statistical packages. As technologies and treatments for 
HIV changes, it was simple to change the Excel format. Financial data was merged 
into the clinical database by patient unique identification number. Care was taken 
to ensure patient privacy and anonymity. Follow-up on patient disease progression 
and clinical markers was performed every four months. Data was gathered on clinical 
markers such as CD4 T cell count and percentage of lymphocytes, CDS T cell count 
and percentage of lymphocytes, ratio of CD4 T cells to CDS T cells, HIV RNA levels 
(viral load), viral genotypic mutations, {32 microglobulin, p24 antigen, cholesterol, 
triglycerides, and weight. Data was also gathered on diagnosis, history of opportunis-
tic infections, antiretroviral medication history, treatments, disease stage, prophalaxis 
medications, and compliance with drug regimens. As patients enter the doctor's office 
at different intervals as well as have lab tests performed at different intervals, all data 
were entered as date of visit or laboratory test and result. As a result, some patients 
have more test results than others. 
Compliance was measured as a binary variable. In the course of the doctor visit, 
7 
the doctor would ask the patient if they took all of their medication as prescribed. If 
the answer was negative, the date was marked as a one for noncompliance on that date, 
otherwise noncompliance was coded as a zero. Disease stage was coded as a discrete 
variable coupled with a date: zero for asymptomatic, one for symptomatic, and two 
for AIDS and the date of the assessment. Patients who were coded as asymptomatic 
for a particular date had no outward symptoms of HIV infection. Patients who were 
coded as symptomatic had increased symptoms of immune dysfunction. Symptoms 
included oral candidiasis, night sweats, and recurrent herpes zoster. Patients were 
defined as having AIDS if they were diagnosed with an opportunistic infection. Note 
that there is monotonicity in the ordering of the disease stages. Once a patient was 
coded as being in a certain stage, the same patient could not revert to an earlier 
stage. For example, if a patient is coded as having AIDS, they could never revert 
back to being symptomatic. 
CD4 T cell counts and percentages, CD8 T cell counts and percentages, /32 mi-
croglobulin, p24 antigen, cholesterol, triglyceride levels, HIV RNA levels, and weight 
were all coded as continuous variables with their corresponding dates. Diagnoses 
were coded as their ICD-9 numeric code as is standard in insurance documentation. 
Antiretroviral and other treatment medications were coded as a date and a binary 
variable that was one if the patient was on that particular drug at that date. Eco-
nomic and demographic variables such as cost, age, gender, insurance status, and 
disability status were also collected. Cost data represents the charge to the patient 
or their respective insurance company. 
In the cohort, there are 28 females and 297 males. The majority of men in the co-
hort were infected by homosexual contact. The women were infected by heterosexual 
contact. The median age is 42 years (range 21-69 years) . In the sample, 78 percent of 
the patients are privately insured, 16 percent are covered by Medi-Care or Medi-Cal, 
and 11 percent belong to health maintenance organizations or have no insurance. 
Patients were heterogeneous with respect to disease stage. Roughly 33 percent 
of the patients came into the clinic asymptomatic. These patients have no outward 
symptoms of HIV disease. One-third were symptomatic. These patients are showing 
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signs of increase immune suppression but have not experienced an opportunistic in-
fection. Oral candidiasis and recurrent herpes zoster are indicative of symptomatic 
HIV infection. One-third of the patients entered the study already having experi-
enced an opportunistic infection. These patients have severe immune depletion and 
are at increased risk of death. Note that AIDS is not classified based on absolute CD4 
T -cell count, only on the presence of an AIDS defining opportunistic infection. The 
reason for this coding will become apparent in the section on nonparametric density 
estimation of CD4+ T -cell counts by disease stage. 
The patients in the study are homogeneous with respect to financial status. Most 
patients in the study are privately insured and well off. These patients generally 
are well educated and well informed about their disease. These patients, for the 
most part, can afford combination antiretroviral therapy. The vast majority of the 
patient in this cohort are on antiretroviral medication. In the era of HAART, 90 
percent of the patients sampled were on combination antiretroviral therapy. The 
culmination of these factors is important because it relates to the issue of compliance 
to the antiretroviral regimen. These patients are well educated about the various 
aspects of the disease and are warned about the ramifications of drug resistance 
due to noncompliance. Studies have shown that patients who are poorer or who 
are intravenous drug users are more likely to be noncompliant with the complicated 
regimens required for highly active antiretroviral therapy (HAART) . Since this patient 
group consists primarily of well educated gay white males, one could argue that 
this specific population would be more likely to be compliant with the therapeutic 
regimens. 
The question ofrepresentativeness is intrinsic to disease cohorts [18]. The question 
of selection bias is especially relevant in a cohort from one outpatient clinic. The 
fact that 73 percent of the population is privately insured and only one percent of 
the population are IV drug users suggests that it is not. However, this population 
can serve as the frontier of medical technology and HIV care. Michael Gottlieb is 
renowned as an HIV specialist. He is credited with the first diagnosis of AIDS in the 
United States and for finding the correlation between CD4 T-cell counts and HIV. He 
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has been on some of the earliest clinical trials and continues to be involved in clinical 
trials and expanded access programs. He utilizes the most advanced technologies such 
as genotypic and phenotypic testing. Thus his patients receive the most advanced 
care medicine can offer. The patient population that he serves offers the best chance 
for compliance in that they are well educated and motivated to be compliant with 
their antiretroviral regimens and are aggressive in the treatment of their disease. In 
this way, this study looks at the frontier of HIV treatment in the outpatient setting. 
Trends in this population will be seen first and then later in a more representative 
population. This study should be viewed in that light. 
Outcomes from an outpatient clinic can differ substantially from clinical trials. 
Clinical trials are highly controlled experiments that test whether one treatment 
regimen is more effective than another. Patients are carefully selected to be homoge-
neous with respect to disease status and other factors deemed important to the trial. 
Patients are also monitored very closely. Subjects who are non-compliant are not 
included in the study and subjects are required to stay on the same treatment for the 
prescribed length of time. In the more general clinical setting of the doctor's office, 
patients enter treatment at different disease stages. Patients are often heterogeneous 
in many different respects. Patient are more likely to switch treatment regimens and 
are more likely to be noncompliant when compared to the clinical trial population. 
Procedures such as viral load (quantitation of the number of HIV RNA copies/ml) 
and CD4+ T-lymphocyte quantitation are done at different frequencies for patients 
depending on disease state, insurance type and other factors . Data of this nature 
are inherently more complex to analyze but also can yield deeper insights into the 
impact of HIV on the more general outpatient population of HIV infected individuals. 
Because of this complexity, standard statistical techniques are often insufficient. 
The analytic approach to the dataset that I collected is an intent-to-treat analysis. 
Although a compliance rate is measured, patients who are noncompliant are not 
dropped from the analysis. The non-compliance rate for this cohort of patients is 30 
percent which is significantly lower than non-compliance rates found in other studies. 
In the clinical setting, patients may be noncompliant to their therapeutic regimen 
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for a variety of reasons: difficulty of regimen, side-effects, or toxicity. To evaluate 
the efficacy of a drug, clinical trials only analyze patients who were compliant to 
the treatment. In the doctor's office results may differ from those seen in a clinical 
trial because there are less stringent controls. To assess the clinical effectiveness of 
antiretrovirals, I conduct intent-to-treat analyses. This should yield results consistent 
with those that physicians are seeing in their outpatient clinics. 
2.2 MACS Data 
Data were obtained from the Multicenter AIDS Cohort Study (MACS) public dataset. 
The MACS is a prevalent cohort that collects data from volunteers at five separate 
centers. The original cohort consisted of 4,954 gay and bisexual men. Follow up was 
every six months. Each visit consisted of physical exams, laboratory tests and ques-
t ionnaires about their condition, treatments, and history of opportunistic infections. 
The cohort was started in 1984, before HIV was isolated. Thus the MACS data con-
tains seronegative patients as well as seroconverters . From April 1987 and September 
1991, the cohort was opened to include minorities, women and partners of members 
of the original cohort . In 1990, visits 14-17, questionnaire on health care cost and 
utilization were given. The details of the characteristics of the MACS are well known 
in the literature [17] . The public data set covers MACS visits 1-17, which covers 
the start of the MACS until October 1, 1992. Subjects in the MACS cohort were 
on antiretroviral treatment ranging from no treatment to mono or dual therapy with 
reverse transcriptase inhibitors. As the data end in 1992 and protease inhibitors were 
approved in 1995, data on protease inhibitors in this population were not available 
on the MACS public data set. 
Cohort studies are especially useful for describing the natural history of HIV / AIDS. 
In these studies, therapeutic interventions are not given according to a protocol; they 
are given to patients on an individualized basis by their outpatient providers. Clini-
cal trials evaluate the efficacy of a specific treatment versus a placebo or a standard 
of care. Cohort studies can be used to estimate effectiveness of a treatment. That 
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is, the effectiveness of a treatment on the population for which it was intended in 
reducing morbidity and mortality due to the illness. Data gathered from these cohort 
studies cannot be readily extrapolated to the general population without accounting 
for selection bias. Inherent biases occurs in these cohort studies when the population 
being studied is not representative of the more general population. This is often the 
case with cohort studies. In HIV, most studies are under-represented by women, 
minorities and intravenous drug users. This fact must be taken into account when 
extrapolating results from the smaller population to the general population. 
The MACS is a significantly larger database and has a more diverse patient pop-
ulation than the database I collected. The dataset that I have collected is clearly 
too homogeneous to be representative of the HIV infected population. However, I 
argue that it is homogeneous in an informative way. The population which I study is 
very well educated and well off. These patients are more likely to receive and afford 
the latest treatments and technologies and are more likely to be compliant. These 
patients represent the frontier of HIV therapy and treatment. Trends in treatment 
are more likely to appear in this population before the more general population. To 
that end, this population is interesting and worth studying. 
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Chapter 3 Estimated Distributions of CD4 T 
Lymphocytes in HIV-1 Infected Patients 
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Abstract 
In the literature, it is standard to assume normality or log normality for CD4 T cell 
counts. To test this assumption, a nonparametric density estimator was applied to 
two different datasets. The first dataset is from the Multicenter AIDS Cohort Study 
(MACS). The second dataset consists of clinical data obtained from an outpatient 
clinic. The second dataset was sufficiently detailed to separate patients and their 
corresponding CD4 T cell counts by disease stage: asymptomatic, symptomatic, and 
AIDS. For each stage, a density estimate was constructed for the CD4 T cell counts. It 
was found for all disease stages that CD4 T cell counts are not distributed Gaussian. It 
was also found that even in the asymptomatic stage, there was a significant decrease 
in CD4 T cell counts as compared to the uninfected population. Thus even if a 
patient has no outward symptoms of HIV infect ion, they could be immunodeficient. 
This suggests that patients should seek treatment early in infection and emphasizes 
the need for more widespread testing. 
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3.1 Introduction 
In the HIV (human immunodeficiency virus) literature, it is standard to assume 
normality or log-normality for CD4 T cell distributions [19, 20, 21]. To test this as-
sumption, a nonparametric density estimator is utilized to estimate the distributions 
of CD4 T cell counts. Two datasets are used. The first dataset comes from the Mul-
ticenter AIDS Cohort Study (MACS). The second database consists of data gathered 
from an outpatient clinic. 
The MACS is a large prevalence database that consists of almost 5,000 participants 
who were at risk for HIV /AIDS at five different sites. Every six months data were 
obtained on CD4 T cell counts as well as other clinical markers. The second dataset 
consists of data from 77 patients chosen at random from an outpatient clinic. Data 
were gathered on CD4 T cell counts as well as other factors in roughly 6 month 
intervals. The MACS is a larger, more broad study than the data collected from a 
private clinic. The data from the private clinic, however, is more detailed and can 
yield insights into clinical progression under various treatment regimens. 
In examining CD4 T cell counts, the analysis is often complicated by non-normality 
and bimodality. Comparisons of populations and levels are not straightforward in 
these cases. Assumptions of normality, in this case, could lead to biased and mis-
leading results. Nonparametric density estimates were constructed using both co-
horts. Estimates were also constructed by disease stage: asymptomatic, symptomatic, 
and AIDS. The resulting CD4 T cell distributions are compared using Kolmogorov-
Smirnov (KS). Kolmogorov-Smirnov is used because it is nonparametric and searches 
over the entire density. Nonparametric tests are preferable especially when there 
exists non-normality, skewness, and bimodality. 
For both datasets, the MACS and the outpatient dataset, it was found that the 
estimated CD4 T cell counts were not distributed Gaussian. Estimates of the CD4 T 
cell distributions for each disease stage were also non-Gaussian. In fact , for the AIDS 
stage, the distribution was bimodal in the MACS population. This result must be 
taken into account when making distributional assumptions about CD4 T cell counts. 
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It was also found that even in patients who are asymptomatic, that is have no 
outward symptoms of HIV infection, there existed a high degree of immunosuppres-
sion of CD4 T cell counts. This suggests that patients should seek treatment early 
in the course of infection to prevent further immune damage and also emphasizes the 
need for more widespread testing. 
3.2 Data 
The methodology discussed in the previous section was applied to data from the 
Multicenter AIDS Cohort Study (MACS) public data set and to data from a private 
HIV clinic. The MACS is a prevalent cohort that collects data from volunteers at 
five separate centers. For each visit there was a physical examination, questionnaires 
and lab tests. The public data set starts at the beginning of the MACS in 1984 and 
ends October 1, 1992 and covers MACS visits 1-17. Subjects in this cohort were 
on therapies ranging from no treatment to combination nucleoside analogue therapy. 
The data end in 1992; consequentially, there are no subjects on protease inhibitors. 
The only selection criteria for the data utilized in this analysis, was seropositivity. 
Observations of CD4+ T-lymphocyte counts on seropositive people yielded 2,166 
patients with 19,998 person-visit observations1 . Approximately 12.2 percent of these 
observations came from AIDS patients and 87.8 percent came from observations from 
subjects who did not have an AIDS defining illness. 
A separate dataset that was smaller but more detailed than the MACS was col-
lected from a private outpatient clinic that specialized in HIV care. Patients were 
selected by a ten percent random sample of all the patients in the practice. The only 
selection criteria was seropositivity2 • In all 77, patients were included in the study. 
Data were gathered on clinical markers such as CD4 and CD8 T cells counts, {32 
microglobulin, p24 antigen and weight . Data were also gathered on disease stage, 
physician diagnosis, antiretroviral treatment, insurance status, and cost. The data 
1 Patients had 1 to 17 CD4 observations. 
2 Seropositivity is defined as the presence of antibodies to HIV. 
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covered the years 1984 to 1994. This dataset is important because it offers more detail 
on patient's disease progression and treatments. Because of this detail it was possible 
to stratify the patients by disease stage: asymptomatic, symptomatic, and AIDS3 . 
Approximately 33 percent of the patients were classified as asymptomatic, 26 percent 
were symptomatic and 41 percent had experienced an AIDS defining opportunistic 
infection. 
3. 3 Analysis 
Repeated CD4 measurements on the same person cannot be considered indepen-
dent [18]. This suggests that a pooled sample of CD4 counts would have some degree 
of correlation. To ascertain the effects of the correlation on the distribution, an inde-
pendent sample was created by randomly sampling one CD4 observation per person. 
This sample is independent, and the standard errors can be calculated in the usual 
fashion; it is, however, inefficient because it does not make use of all the data. It has 
also been shown that subsampling non-independent but stationary data can only re-
sult in poorer estimators [22, 23]. An independent subset ofthe MACS was created by 
taking a random subsample of one CD4 observation from each person. This resulted 
in a dataset of 2,166 independent observations. The nonparametric density distribu-
tion of the independent sample was estimated (Figure 1) . The estimated mean was 
474.56 cells/mm3 , the standard deviation was 306.02 cells/mm3 , and the standard 
error of the mean was 6.60 cells/mm3 . The estimation procedure was repeated using 
the full sample of 19,988 observations (see Figure 2). The mean was 483.27 cells/mm3 , 
the standard deviation was 298.49 cells/mm3 . After 10,000 bootstrap replications the 
standard error of the mean was 5. 70 cells/mm3 . The two distributions were then com-
pared nonparametrically using the Kolmogorov-Smirnov (KS) test (see Table 1). The 
asymptotic KS statistic (KSa) was 1.35 and the prob > KSa was greater than 0.05. 
Therefore, the two distributions are not significantly different at the alpha equals 
3 I use the 1987 CDC definition that defined AIDS as a n specified opportunistic infection without 
regard to the level of CD4 T cells. 
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0.05 level. The nonparametric distribution was then plotted against the Gaussian 
curve. By inspection of the curves, one can see there exists a definite skew in the 
nonparametric distribution. A box plot of the data confirms this, see Figure 2. This 
suggests that the CD4 distribution of HIV infected patients may not be Gaussian. 
The distribution was then tested against the hypothesis of normality [24]. The hy-
pothesis of normality was rejected p < 0.001 by KS. The Gaussian distribution does 
not present a good fit for the infected population due to the skewness and truncation 
at zero. Several other parametric distributions such as the log normal, exponential 
and Weibull were fit to the distribution with less success. One must take this re-
sult into account when comparing different populations of HIV infected individuals 
and comparing the HIV population to the uninfected population. The Kolmogorov-
Smirnov test is completely nonparametric and searches the entire distribution, and 
thus appropriate for this type of situation. The square root transformation is applied 
to the CD4 counts, as standard in the literature [18, 25, 26, 27] and the CD4 density 
was reconstructed and given in Figure 3. The mean of this distribution is 20.74 with 
bootstrapped standard error 0.135. Using the Kolmogrov-Smirnov test for normality, 
the hypothesis that the estimated distribution is distributed Gaussian is rejected at 
p=O.Ol. 
To further illustrate the necessity of testing the normality assumption when con-
structing estimates, the nonparametric density distribution of CD4 counts was con-
structed using only observations that came from patients diagnosed with AIDS. The 
square root transformation is performed to normalize the data. The mean of this 
distribution is 13.62 with a bootstrapped standard error of the mean 0.164. Figure 4 
shows that for the AIDS population from the MACS data, not only is the resulting 
distribution non-Gaussian (p=O.OOOl), it is bimodal. The bimodality in the AIDS 
stage is important to consider when constructing hypothesis tests that rely on under-
lying normality. It is also important to consider when comparing means and variances 
of CD4 counts in the AIDS stage. 
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3.3.1 MACS Cohort Compared With the Outpatient Cohort 
The nonparametric density of CD4 T cell counts was estimated utilizing the en-
tire sample from the outpatient data. The mean for this distribution was 365.42 
cells/mm3 . After 10,000 replications of the bootstrap, the standard error of the mean 
was estimated to be 27.52 cells/mm3 . The shape of the distribution is similar to 
that of the MACS CD4 T cell distribution; see Figure 5. The distribution was then 
tested against the hypothesis of normality by KS. Normality was rejected at p=O.OOl. 
The MACS CD4 T cell distribution was then compared to the estimated CD4 T cell 
distribution from the outpatient dataset by Komologorov-Smirnov. They were found 
to be statistically different at the p=0.001 level; see Table 2. The larger standard 
errors are more than likely due to the smaller sample size of the outpatient data. The 
difference in the means can possibly be explained by the fact that the MACS pop-
ulation has only 12.2 percent of the CD4 T cell observations from the AIDS disease 
stage, whereas the outpatient database has 41 percent of the observations from the 
AIDS stage. As the likelihood of AIDS increases as CD4 T cells decrease [6], this 
could bias the mean downward. 
Since the overall distribution of CD4 T cells can be viewed as a mixture of all of 
the distributions from each disease stage, the nonparametric CD4 T cell density distri-
bution was constructed for each disease stage. The outpatient database is sufficiently 
detailed to segregate patients into all three disease stages. The MACS could only 
be separated into observations from the AIDS stage and observation from patients 
without AIDS (the noAIDS distribution). The CD4 T cell distribution from AIDS 
observations from t.h P. MACS had a mean of 251.07 cells/mm3 with bootstrapped 
standard error of the mean 11.98 cells/mm3 ; see Figure 6. The AIDS CD4 T cell 
distribution from the outpatient dataset had a mean of 167.92 cells/mm3 with boot-
strapped standard error of 28.37 cells/mm3 ; see Figure 7. The hypothesis that the 
two distributions are the same is rejected by KS at p= 0.001 level; see Table 3. The 
noAIDS CD4 distribution from the MACS had a mean of 409.21 cells/mm3 with 
a bootstrapped standard error of the mean of 6.49 cells/mm3 ; see F igure 8. The 
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noAIDS CD4 distribution from the outpatient data had a mean of 450.11 cells/mm3 
with bootstrapped standard error of 28.62 cells/mm3 ; see Figure 9. Standard ANOVA 
fails to reject the hypothesis that the two distributions are the same, p=0.3421, while 
KS rejects with p=0.040. This illustrates the necessity of taking into account the 
underlying distributional assumption, especially in small samples. 
3.3.2 Densities by Disease Stage 
The outpatient data was sufficiently detailed to separate patients into three distinct 
disease stages: asymptomatic, symptomatic, and AIDS. AIDS was defined as diag-
nosis with an opportunistic infection regardless of CD4 T cell count. Patients who 
were coded as symptomatic had increasing symptoms of HIV infection but were not 
diagnosed with an opportunistic infection. Symptoms included oral candidiasis, night 
sweats, and recurrent herpes zoster. Patients who were considered asymptomatic had 
no outward symptoms of HIV infection. The AIDS CD4 distribution had a mean of 
167.92 cells/mm3 with bootstrapped standard error of 28.37cells/mm3 . KS tests of 
normality rejected the hypothesis that the estimated distribution was Gaussian at 
p=O.OOl. The mean for the symptomatic population was 394.00 cells/mm3 with a 
bootstrapped standard error of the mean of 30.74 cells/mm3 . The shape of the dis-
tribution was roughly normal with a distinct skew; see Figure 10. The hypothesis 
of normality was rejected by KS at p= O.OOl. The mean of the asymptomatic CD4 
T cell distribution was 550.0 cells/mm3 with a bootstrapped standard error of the 
mean of 51.62 cells/mm3 . The estimated distribution has a definite skew and was bi-
modal; see Figure 11. The hypothesis of normality is also rejected by KS at p=O.OOl. 
One might expect that the CD4 T cell distribution of asymptomatic patients would 
be similar to CD4 distribution of the uninfected population. However, it was found 
that this was not the case. The distribution of CD4 T cell counts for the uninfected 
population is N(1017,329) [28]. The asymptomatic CD4 distribution is significantly 
different than the uninfected population by KS at the p=0.001 level. This suggests 
that HIV-infected patients who have no outward symptoms could still have a high de-
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gree of immunosuppression. The results also strongly suggest that CD4 T cell counts 
are not distributed Gaussian in HIV infected patients. 
3.4 Discussion 
In both datasets it was found that the estimated CD4 T cell distributions were dis-
t inctly non-Gaussian. Thus modeling CD4 T cell counts distributions, trajectories 
and other analyses utilizing CD4 T cell counts must take this result into account. If 
normality is not a valid assumption, the nonparametric techniques should be consid-
ered. Failure to take distributional assumptions into account can lead to biased or 
misleading results. 
It was also found that the CD4 distribution from the MACS were significantly 
different from the outpatient dataset. This may be due to the relatively small sample 
size of the outpatient data or an artifact of selection bias. There could also exist 
something systematically different about the outpatient dataset. However, in both 
datasets the CD4 distributions were all non-Gaussian. 
The fact that there was a high degree of CD4 T cell depletion in the asymptomatic 
stage suggests that there exist a high degree of immune dysfunction even in patients 
who have no outward symptoms. This suggests that patients should seek treatment 
early in their disease course to prevent further immune system damage. The results 
also emphasize the need for more widespread testing. 
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:~ 
D 
e 
n 
s 
i 
t 
~ 
IHDP _CD4 
e 
0 . 001· 
e.eees 
e 
21 
PEili3ili::rrr3ilEiil!:'TIGE:liWI'iliB•--- -·. • • • • 
see 1sea 
INDP _CD4 
INDP _CD4 
Figure 3.1: a. Box plot of 2,166 independent CD4 T cell draws from the MACS. b. 
Solid line: nonparametric density of CD4 T cell counts estimated from independent 
draws from t he MACS. Broken line: data fitted to the Gaussian distribution. 
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Figure 3.2: a. Box plot of 19,988 CD4 T cell observations from the MACS. b. Solid 
line: nonparametric density estimate of the CD4 T cell counts from the MACS. 
Broken line: data fitted to the Gaussian distribution. 
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Figure 3.3: a . Box plot of square root CD4 T cell observations taken from the MACS. 
b. Solid line: nonparametric density estimate of CD4 T cell counts taken from the 
MACS. Broken line: data fitted to the Gaussian distribut ion. 
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Figure 3.4: a. Box plot of square root CD4 T cell observations taken from the AIDS 
stage of the MACS. b. Solid line: nonparametric density estimate of CD4 T cell 
counts taken from the AIDS stage of the MACS. Broken line: data fitted to the 
Gaussian distribution. 
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F igure 3.5: a . Box plot of 600 CD4 T cell observations from the outpatient dat aset. b. 
Solid line: nonparametric density estimate of CD4 T cell counts from the outpatient 
dataset. Broken line: data fitted to the Gaussian distribution. 
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Figure 3.6: a. Box plot of CD4 T cell counts taken from the AIDS stage of the MACS. 
b . Solid line: nonparametric density estimate of CD4 T cell counts taken from the 
AIDS stage of the MACS. Broken line: data fitted to the log normal distribution. 
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Figure 3.7: a. Box plot of CD4 T cell counts taken from the AIDS stage of the 
outpatient dataset. b. Solid line: nonparametric density estimate of CD4 T cell 
counts taken from the AIDS stage of the outpatient dataset. Broken line: data fitted 
to the log normal distribution. 
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Figure 3.8: a. Box plot of CD4 T cell counts taken from patients without AIDS from 
t he MACS. b. Solid line: nonparametric density estimate of CD4 T cell counts taken 
from patients without AIDS from the MACS. Broken line: data fitted to the Gaussian 
distribution. 
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Figure 3.9: a. Box plot of CD4 T cell counts taken from patients without AIDS from 
the outpatient dataset. b. Solid line: nonparametric density estimat e of CD4 T cell 
counts taken from patients without AIDS from the outpatient dataset. Broken line: 
data fitted to the Gaussian distribution. 
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Figure 3.10: a. Box plot of CD4 T cell counts taken from the symptomatic stage of 
the outpatient dataset. b. Solid line: nonparametric density estimate of CD4 T cell 
counts taken from the symptomatic stage from the outpatient dataset. Broken line: 
data fitted to the Gaussian distribution. 
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Figure 3.11: a . Box plot of CD4 T cell counts taken from the asymptomatic stage of 
the outpatient dataset . b. Solid line: nonparametric density estimate of CD4 T cell 
counts taken from the asymptomatic stage of t he outpatient dataset. Broken line: 
data fitted to t he Gaussian distribution. 
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Chapter 4 Nonparametric Density Estimation of 
Repeated Measures Data: An Application to CD4 
T Cell Counts and Immune Reconstitution 
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Abstract 
Analysis of longitudinal data, such as clinical markers like CD4+ T-lymphocyte (CD4) 
counts, are often complicated by the fact that there exists within-person correlation 
between the observations over time and there is often an unequal number of obser-
vations per person. Due to individual variation and differing responses, comparisons 
of means and variance of these levels may not be sufficient. In the specific case of 
CD4 counts, there might exist bimodality in the distribution, even when transfor-
mations such as the square root or log are performed. Assumptions of Gaussian 
distributions could lead to serious errors in cases of bimodality. Comparisons and 
analysis using means and standard errors could also be misleading. By employing 
a nonparametric density estimator, one can overcome these difficulties and compare 
distributions and levels. This paper outlines methodology to construct a nonparamet-
ric density estimator that is unbiased to order O(h2), consistent in mean square, and 
takes into account correlation and unequal number of observations. An application 
of the method is used to construct nonparametric density estimates of CD4 counts 
from both the Multicenter AIDS Cohort Study and a database of patients receiving 
Highly Active Anti Retroviral Treatment (HAART). It was found that the resulting 
distributions were distinctly non-Gaussian; therefore, use of traditional methods that 
assume underlying normality could yield misleading results. It was also found that 
the CD4 distribution in patients on HAART was significantly different from the CD4 
distribution from the uninfected population. The results suggest that, on average, the 
CD4 levels of patients on HAART do not approach that of the uninfected population. 
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4.1 Introduction 
CD4 T-lymphocyte (CD4) counts are important in monitoring and predicting the 
course of HIV infection. The onset of AIDS occurs when the level of CD4 counts is 
low enough to cause severe immunosuppression. Knowing the distribution of CD4 
counts and the likelihood of AIDS is beneficial to implement effective prophalaxis for 
opportunistic infections. This is especially true when the prophalaxis can be toxic, 
invasive, or expensive. Repeated measures data are often complicated by correlation, 
and missing data. In examining CD4 counts, the analysis is also complicated by non-
normality and in some cases bimodality. Estimation and comparisons of populations 
and levels are not straightforward in these cases. 
It has been hypothesized that CD4 counts could be brought up to levels similar 
to the uninfected population if the virus could be suppressed long enough by combi-
nation antiretroviral therapy [11]. To test this, one could compare the distribution 
of CD4 counts from patients on combination antiretroviral therapy with the distri-
bution of the uninfected population. The former distribution could be bimodal due 
to differing responses to treatment as well as genetic factors. In the clinical setting, 
often one set of patients responds favorably to treatment while other patients have 
a suboptimal response. The underlying distribution could be a mixture of several 
distributions. Looking at means and variances would be misleading in these cases. 
Thus comparisons to the uninfected population, whose distribution is reported to be 
Gaussian(1017,329) [28], could be misleading. 
This paper outlines methodology for such a comparison and constructs a nonpara-
metric density estimator that is unbiased and consistent in mean square. Because 
sequential observations of markers from the same individual are correlated [18], one 
cannot utilize the full data set and assume independence. It would also be inefficient 
to utilize only an independent subsample of the data [22]. The method described 
takes into account the within person correlation and is robust to unequal numbers of 
observations per person. The bootstrap is employed to estimate the standard errors. 
This method is applicable to data from the Multicenter AIDS Cohort study 
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(MACS) and a database of patients receiving Highly Active Anti Retroviral Ther-
apy (HAART). To demonstrate the inefficiency of subsampling, density estimates 
of CD4+ T-lymphocyte (CD4) counts were constructed utilizing the data from the 
MACS. A similar density estimation was constructed using an independent subset 
of the MACS. The independent distribution was not significantly different from the 
distribution that utilized the full sample and was less efficient. The patients were 
then segregated by AIDS status. Patients who had experienced an opportunistic 
infection were defined as having AIDS. It was found that the resulting distribution 
was bimodal, underscoring the importance of knowing the underlying distributional 
assumptions. The MACS distribution was then compared to the CD4 distribution 
constructed from the patients on HAART. The resulting distributions were compared 
and found to be significantly different. The distribution that was constructed from 
patients on HAART was compared to the hypothesized distribution of CD4 counts 
from the uninfected population. It was found that the CD4 distribution from the 
HAART patients was significantly different from the uninfected distribution, suggest-
ing that patients in this sample did not experience a sustained CD4 T-lymphocyte cell 
increase great enough to be considered immune reconstitution. In the next section, 
the model is presented. The model is then applied to HIV data, and the results are 
presented. 
4.2 Inference Procedures 
Let XiJ be the jth observation on person i, i = 1, ... , n; j = 1, ... , k. Non parametric 
estimates were constructed using 
fn(x) ~ n!h t.tK C\-x ) (4.1) 
where the kernel function, K, can be any probability density function. 
Let K =the Normal kernel, 
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1 ( t
2
) K(t) = ¢ (t) = V'i/ffexp - 2- (4.2) 
thus every data point receives Gaussian weight. The sum of these weights make 
up the CD4 density estimate, 
n k ( ) A 1 1 Xij - X fn(X, h) = n _ 1 L L ~¢ A h ' i = l j = l (]' (]' (4.3) 
where a is the standard deviation of the x~jsK 
Let the bandwidth, h = ( 4/3)115&n- 115 , where h is the Normal reference rule band-
width for a Normal kernel [29]. 
The expectation of j ( x) equals 
A J 1 (X-8) J Ef(x) = hK -h- f(s)ds = K(t)f(x- ht)dt (4.4) 
By Taylor expansion .. . 
E}(x) = f(x) J K(t)- hj'(x) J tK(t) + ~hO f" (x) J t2 K(t) + ... (4 .5) 
Since K equals the normal kernel, ¢ , 
J K(t) = 1, J tK(t) = 0, and J t 2 K(t) = 0'2 < oo. (4.6) 
Therefore, E}(x) = f(x) to order O(h2), thus 
(4.7) 
In most longitudinal studies, observations between subjects can be considered 
independent. It is t he within patient observations t hat are correlated. One can 
construct the underlying density of non-independent data, but one must take into 
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account the covariance terms when calculating the variance. The variance equals 
Var<fn) = E ( nD~DhD t. t, [x ( x, ~ x)- hf(x)] [x ( x; ~ x) _ hf(x)l) 
(4.8) 
where J(x) is the expected value of fn· Let Zi = K (x;hx) and the variance can be 
written as 
Var(jn(x)) = (n2 : 2 h2 ) ~ ~ Cov(zi , zj) (4.9) 
This can be extended to allow for k of different lengths for each person by letting 
k = max(ki)· Note that for each person, i, there exists at most k observations. Thus 
there will be at most nk2 non zero covariance terms. Since K = ¢, zi and Zj are 
bounded. By the Cauchy-Schwartz inequality and the boundedness of K, there exists 
an M < oo such that ICov(zi, Zj) f~ M ;therefore: 
The k's drop out of the equation due to the fact that it was not assumed that 
correlations diminish over time. Furthermore, define ax,n = jlb thus 
lim nax n-+ 00 
n -+oo ' 
(4.11) 
Therefore, by Scott [29] , j is non parametric and consistent in mean square. These 
results stem from the fact that there exists independence between t he subjects. Thus 
only nk2 terms are non-zero. Moreover, the fact that the k 2 term cancels ensures 
that the estimator is robust to unequal numbers of observations. Note also that h is 
constructed so that n goes to infinity faster than h goes to zero. Thus, E(j) -+ f 
and j -+ f as n -+ oo. 
One could also subsample 1 observation from each person and get at most k iid 
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samples which would all be unbiased and consistent; but it would also be inefficient 
[22] . Estimating the variance empirically can be achieved through use of the boot-
strap. Exploiting the fact that there exists between subject independence, one can 
bootstrap by rows and preserve the correlation structure. This is similar to the mov-
ing blocks bootstrap with block length k [30]. Let i = 1, 2, ... , B denote the bootstrap 
samples, and let e; be the values of the statistic computed using each of these samples. 
The standard errors can be estimated by 
where 
B 
{j* = ~ ~ B* k L...t t 
i=l 
(4.12) 
(4.13) 
The problem of edge effects come into play when the data are discontinuous or 
truncated. Boundary kernels, variable bandwidths, and reflective boundary tech-
niques can be used to address these problems. Boundary kernels are sensitive to the 
choice of support intervals; thus one must be careful in the selection of the support 
interval. The kernel for a given point, xi, covers the interval (xi - h, Xi+ h). If the 
data are truncated at x = 0, the kernel interval should be [0, Xi+ h), which is nar-
rower than 2h. One solution is to use the wider interval (0, 2h) for all Xi E [0, h) [31]. 
This is the variable bandwidth technique. The reflection boundary technique can 
be implemented if the discontinuity is at x = 0 and the data are nonnegative [29]. 
The technique is used on data that have been reflected about x = 0. Estimates are 
computed by taking the original estimates and doubling them for x ~ 0. The variable 
bandwidth technique is implemented on data in the AIDS stage, when CD4 counts 
approach zero. 
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tion of selection bias is especially true of a single private clinic that services one 
geographic location. These patients are on and can afford the latest treatments and 
many are involved in clinical trials. The MACS data, on the other hand, was col-
lected from five different centers and covered a wider spectrum of patients. Whether 
or not the data are representative is not the focus of this paper. The fact that private 
data has 35 percent of the observations coming from the AIDS population and 73 
percent of the patients privately insured certainly is not representative of the entire 
population. We will use the methodology in the previous section to compare the CD4 
distributions from the private dataset, the MACS dataset, and to the hypothesized 
uninfected distribution using a Kolmogorov-Smirnov test. Kolmogorov-Smirnov (KS) 
is appropriate for data of t his type because it is distribution-free and searches over 
and compares the entire density. Nonparametric tests are preferable especially when 
there exists non-normality, skewness, and/or bimodality. 
4.4 Analysis 
Repeated CD4 measurements on the same person cannot be considered indepen-
dent [18] . This suggests that a pooled sample of CD4 counts would have some degree 
of correlation. To ascertain the effects of the correlation on the distribution, an in-
dependent sample was drawn by randomly sampling one CD4 observation per person 
and estimating t he nonparametric density. This sample is indep endent and the stan-
dard errors can be calculated in the usual fashion; it is, however, inefficient because 
it does not make use of all the data. It has also been shown that subsampling non-
independent but stationary data can only result in poorer estimators [22, 23]. An 
independent subset of the MACS was created by taking a random subsample of one 
CD4 observation from each person. This resulted in a dataset of 2,166 independent 
observations. The nonparametric density distribution of t he independent sample was 
estimated (Figure 1). The estimated mean was 474.56, the standard deviation was 
306.02, and the standard error of the mean was 6.60. The estimation procedure was 
repeated using t he full sample of 19,988 observations (see Figure 2). The mean was 
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483.27, and the standard deviation was 298.49. After 10,000 bootstrap replications 
the standard error of the mean was 5.70. The two distributions were then com-
pared nonparametrically using the Kolmogorov-Smirnov (KS) test (see Table 1). The 
asymptotic KS statistic (KSa) was 1.35 and the prob > KSa was greater than 0.05. 
Therefore, the two distributions are not significantly different at the alpha equals 
0.05 level. The nonparametric distribution was then plotted against the Gaussian 
curve. By inspection of the curves, one can see there exists a definite skew in the 
nonparametric distribution. A box plot of the data confirms this; see Figure 2. This 
suggests that the CD4 distribution of HIV infected patients may not be Gaussian. 
The distribution was then tested against the hypothesis of normality [24] . The hy-
pothesis of normality was rejected p < 0.001 by KS. The Gaussian distribution does 
not present a good fit for the infected population due to the skewness and truncation 
at zero. Several other parametric distributions such as the log normal, exponential 
and Weibull were fit to the distribution with less success. One must take this re-
sult into account when comparing different populations of HIV infected individuals 
and comparing the HIV population to the uninfected population. The Kolmogorov-
Smirnov test is completely nonparametric and searches the entire distribution, and 
thus appropriate for this type of situation. The square root transformation is applied 
to the CD4 counts, as standard in the literature [18, 25, 26, 27] and the CD4 density 
was reconstructed and given in Figure 3. The mean of t his distribution is 20.74 with 
bootstrapped standard error 0.135. Using the Komologrov-Smirnov test for normal-
ity, the hypothesis that the estimated distribution is distributed Gaussian is rejected 
at p=O.Ol. 
To further illustrate the necessity of testing the normality assumption when con-
structing estimates, the nonparametric density distribution of CD4 counts was con-
structed using only observations that came from patients with AIDS. The square root 
transformation is performed to normalize the data. The mean of this distribution is 
13.62 with a bootstrapped standard error of the mean 0.164. Figure 4 shows that 
for the AIDS population from the MACS data, not only is the resulting distribu-
tion non-Gaussian (p=0.0001), it is bimodal. In the AIDS period, CD4 counts go to 
42 
zero, thus truncation at zero becomes a significant factor and techniques to account 
for edge effects must be used. Figure 5 shows the same distribution with a variable 
bandwidth for Xi E [0, h). Accounting for edge effects did not substantially change 
the distribution. The bimodality in the AIDS stage is important to consider when 
constructing hypothesis tests that rely on underlying normality. It is also important 
to consider when comparing means and variances of CD4 counts in the AIDS stage. 
4.4.1 HAART Data 
The nonparametric density of CD4 counts was estimated utilizing t he entire sample 
from the private data. The mean for this distribution was 274.02 with standard error 
195.00. The bootstrapped standard error of the mean was estimated to be 12.65 after 
10,000 replications. The shape of the estimated distribution, shown in Figure 6, is 
skewed. The hypothesis of normality was rejected by KS, p= O.OOl. The MACS and 
the private data set distribution were compared by Kolmogorov-Smirnov and found to 
be significantly different at the p=0.001 level; see Table 2. The larger st andard errors 
are more than likely due to the smaller sample size and shorter follow up period in the 
private data set. The difference in means can possibly be explained due to the fact 
that the MACS data set has only 12.2 percent of its observations coming from AIDS 
patients whereas t he private dataset has approximately 35 percent of the observations 
coming from the AIDS st age. This could bias t he mean downward. 
The square root transformation was performed on the CD4 counts in attempt to 
normalize the data. The mean of the estimated distribution was 15.48 with boot-
strapped standard error of the mean 0.385; see Figure 7. Normality is rejected by KS 
wit h p= 0.0385. These results strongly suggest t hat the distribution of CD4 counts in 
HIV infected individuals are not distributed Gaussian. 
To test the hypothesis of immune reconstitut ion in this population, the CD4 
distribution was compared against the Gaussian(1017, 329) [28]. The hypothesis that 
the two distributions are similar was rejected by KS, p= O.OOOl. The same procedure 
was implemented to construct the distribution of CD8 counts. The mean of the 
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resulting distribution was 915.52 with bootstrapped standard error of the mean 12.65. 
The CDS distribution from the MACS was compared to the CDS distribution from 
the private data set. The estimated distributions were not significantly different at 
p=0.091S. However, when the CDS distribution from the private data was compared 
to the Gaussian(614,234) [2S], the distribution of CDS counts from the uninfected 
population, they were statistically significant p=0.001 by KS. The results suggest 
that patients in this sample did not experience an increase in CD4 counts consistent 
with the hypothesis of immune reconstitution. 
4. 5 Discussion 
A nonparametric density estimator was implemented on correlated data with unequal 
number of observations. Using this method, it was found that the estimated CD4 
distributions from the MACS and from patients on HAART were distinctly non-
Gaussian. Thus it is recommended that the assumption of normality, especially in 
the case of CD4 counts, be verified before parametric methods are used. If normality 
is not a valid assumption, then non-parametric techniques should be considered. The 
gain in efficiency from this estimator is not as great as one would hope. In the 
population that was large enough to check, there was a .9 decrease in the standard 
error of the mean. However, most samples are not large enough to warrant taking 
one observation from each person to obtain an independent sample. This is the real 
gain from this method. One can construct and compare estimates without the need 
for complete independence. 
The results also suggest that, in this population, patients on combination anti 
retroviral therapy did not experience immune reconstitution. That is, their CD4 and 
CDS levels did not increase to the levels of uninfected people. This discouraging fact 
might be due to patient failure to adhere to the drug regimen or HIV resistance. 
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4.6 Conclusion 
This paper develops a methodology for comparing distributions where the observa-
tions making up the distributions are not fully independent, have unequal numbers of 
observations, and are distinctly non-normal. The method is nonparametric, unbiased 
to order O(h2), and consistent in the mean square. It is also easy to implement using 
GAUSS or other readily available statistical packages. Failure to consider these data 
limitations when constructing test statistics can yield misleading results. This paper 
also finds that patients on HAART did not experience immune reconstitution. 
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Figure 4.1: a. Box plot of 2,166 independent CD4 T cell draws from the MACS. b. 
Solid line: nonparametric density of CD4 T cell counts estimated from independent 
draws from the MACS. Broken line: data fitted to the Gaussian distribution. 
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Figure 4.2: a . Box plot of 19,988 CD4 T cell observations from the MACS. b . Solid 
line: nonparametric density estimate of the CD4 T cell counts from t he MACS. 
Broken line: data fitted to the Gaussian distribution 
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Figure 4.3: a. Box plot of square root CD4 T cell observations taken from the MACS. 
b . Solid line: nonparametric density estimate of CD4 T cell counts taken from the 
MACS. Broken line: data fitted to the Gaussian distribution. 
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Figure 4.4: a. Box plot of square root CD4 T cell observations taken from the AIDS 
stage of the MACS. b. Solid line: nonparametric density estimate of CD4 T cell 
counts taken from the AIDS stage of the MACS. Broken line: data fitted to the 
Gaussian distribution. 
49 
SQRT_CD4 
0 20 49 
SQRT_CD4 
0 . 04 
D 
e 
n 
$ 
i 
t 
!l 
e.e2 
e 
SQRT_CD4 
.. 
Figure 4.5: Nonparametric density estimate of square root CD4 T cell counts taken 
from patients with AIDS in the MACS and corrected for edge effects. 
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Figure 4.6: a. Box plot of square root CD4 T cell counts from the HAART dataset. 
b. Solid line: nonparametric density estimate of CD4 T cell counts taken from the 
HAART dataset. Broken line: data fitted to the Gaussian distribution. 
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Figure 4. 7: a. Box plot of square root CD4 T cell counts from the HAART dataset. 
b. Solid line: nonparametric density estimate of CD4 T cell counts from t he HAART 
dataset. Broken line: data fitted to the Gaussian distribution. 
52 
4.8 Tables 
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N Mean Standard Error 
of Mean 
Independent MACS 2166 474.56 6.60 
Full Sample MACS 19988 483.27 5.70 
Asymptotic KS Statistic 1.33 p=0.08 
Table 4.1: Independent MACS versus the full MACS 
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Sample Mean Standard Standard Error of p 
Error Mean (Bootstrapped) (versus Normal) 
Full Sample (MACS) 483.27 298.48 5.70 0.001 
Square Root CD4 (MACS) 20.74 7.27 0.0135 0.01 
AIDS Observations (MACS) 13.62 3.20 0.1640 0.0001 
Table 4.2: Testing t he null hypothesis of normality 
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Dataset N Mean Standard Error 
of Mean 
HAART dataset 1534 274.25 12.65 
MACS dataset 19988 483.27 5.70 
KS test of equality of distributions p-0.001 
Table 4.3: Testing the equality of distributions from the MACS and HAART dat a 
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Mean Standard Error 
HAART dataset 274.25 195.01 
Uninfected population 10 17 329.00 
KS test of equality of distributions p=0.0001 
Table 4.4: Testing the equality of distributions from uninfected people and the p a-
t ient s in the HAART dataset 
Sample Mean 
CD4 (HAART dataset) 274.25 
Square root CD4 (HAART) 15.475 
57 
Standard 
Error 
195 
5.93 
Standard Error of 
Mean (Bootstrapped) 
12.62 
0.3800 
p 
(versus Normal) 
0.001 
0.0385 
Table 4.5: Testing the null hypothesis of normality for t he HAART dataset 
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Chapter 5 Clinical Failure of Highly Active 
Antiretroviral Therapy in HIV-1 Infected Patients 
59 
Abstract 
Background: Dramatic reductions in morbidity and mortality from HIV /AIDS have 
been attributed to the introduction of highly active antiretroviral therapy (HAART). 
To assess the long-term effects of HAART, we retrospectively examined 213 patients 
on long-term HAART. 
Methods: 213 HIV-1 infected patients from an outpatient clinic were retrospec-
tively evaluated after a median of 30 months on HAART. Patients entered the study 
when first placed on HAART and were followed-up until May 1998. The primary 
endpoint was diagnosis with an AIDS defining condition. 
Results: Median time until clinical failure for patients on long-term HAART was 
585 days. In multivariate proportional hazards analyses for subjects with baseline 
CD4 T-cell counts of <100, 100-199, 200-400, and 400+ cells/mm3 , the relative haz-
ard (RH) of progression was 9.992, 4.221, and 2.991 respectively (p<0.01). Baseline 
viral load was not significant. Patients with greater initial responses to HAART 
had decreased risk of progression, RH=0.0722 p=0.0016. Increases in viral load in-
creased risk of progression, RH=l.421, p=O.OOOl. Increasing CD4 cell counts over 
time reduced the risk of progression, RH=0.934, p=0.010. Patients diagnosed with an 
opportunistic infection (OI) prior to initiation of HAART were five times more likely 
to progress than other patients, RH=5.415 p=O.OOl. Median time until clinical failure 
was 399 days for patients with a previous OI. Patients naive to antiretrovirals had 
reduced risk of progression compared with those pretreated, RH=0.417 (p=0.039). 
Conclusions: Despite initial decreases in HIV RNA levels, an unexpectedly high 
level of clinical failure was found in patients on long-term HAART with a median 
failure time of 585 days. 
Keywords: HAART, clinical failure, disease progression, HIV 
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5.1 Introduction 
The use of highly active antiretroviral therapy (HAART) to treat HIV disease using 
combinations of reverse transcriptase and protease inhibitors has led to dramatically 
reduced morbidity and prolonged life in HIV-1 infected patients [10, 32] The initiation 
of HAART rapidly and significantly reduces the levels of virus replication in the 
peripheral blood [33, 34, 35] . In the HIV-infected patient, higher baseline levels ofHIV 
RNA and lower baseline levels of CD4+ T lymphocyte cells in the peripheral blood are 
strongly predictive indicators of disease progression [36, 25]. However, the prognostic 
values of HIV-1 RNA levels and CD4+ T-cell counts are poorly defined in patients 
on long-term HAART and for patients with more advanced disease progression, such 
as those with AIDS defining illnesses and severely depleted CD4+ T-cells. As the 
treatment of HIV infected patients using HAART is relatively recent, little is known 
about long term effectiveness. 
Unfortunately, in the clinical setting, many therapeutic regimens fail within weeks 
to months after initiation, prompting the administration of salvage therapy with 
a different combination of drugs [37, 38] These regimens are intended to prevent 
the emergence of drug resistant viral isolates. Many salvage therapeutic regimens 
ultimately fail, however, due to cross-resistance of viral isolates. Moreover, it may 
not be possible to find a combination of drugs to which there would not be pre-existing 
resistance. 
Long-term effectiveness of HAART is poorly understood. The objectives of this 
study were to delineate the factors associated with disease progression in an unse-
lected cohort of HIV-1 infected patients on long term HAART. Survival analysis was 
performed to assess the clinical failure rate of initial HAART and subsequent salvage 
regimens, as determined by diagnosis with an AIDS defining condition, and to assess 
the median time until clinical failure. The parameters surrounding clinical failure 
were assessed to yield insight as to the long-term effectiveness of HAART and its 
potential to control HIV-disease progression. 
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5.2 Methods 
5.2.1 Study Subjects 
The factors that have previously been associated with disease progression in HIV in 
large cohorts have been baseline quantitative HIV-1 RNA levels [36, 39] and baseline 
CD4 T cell count [25, 40]. These studies indicate that HIV-1 RNA levels (viral load) 
are strongly predictive of HIV disease progression. However, the relative prognos-
tic value of CD4 T cell count and viral load remains poorly defined in cohorts on 
long-term HAART and for patients with advanced disease. Most of the studies to 
date have focused on patients who had high CD4 T cell counts and were relatively 
asymptomatic [36, 41]. In the clinical setting, physicians treat patients in all stages 
of the disease. 
The data presented here are from an unselected cohort of outpatients. We ret-
rospectively analyzed 213 patients from clinical chart data collected from December 
1996 until May 1998. All patients were on individualized treatment regimens and 
were on HAART continuously for a median of 30 months. HAART, in this study, 
is defined as a combination of three or more antiretrovirals where at least one is a 
protease inhibitor. In most of the patients it was necessary to administer a salvage 
regimen consisting of different combinations of antiretrovirals due to intolerance or 
rising plasma HIV-1 RNA levels. 
The study population consisted of 195 men and 18 women. The median age 
at baseline was 41 years. Plasma HIV-1 RNA levels and CD4 T-cell counts were 
performed, on average, every other month. Median HIV -1 RNA at baseline was 
4.239 log copies/ml (range, 1-5.8 log copies/ml). Median baseline CD4 cell count 
was 230 cells/mm3 (range, 0-1011 cells/ml). Thirty-seven (17 percent) patients were 
antiretroviral naive before starting HAART and 32 (15 percent) had experience with 
three or more reverse transcriptase inhibitors before starting HAART. Opportunistic 
infections were diagnosed in 51 pat ients before the start of HAART. Table 1 lists the 
characteristics of patients at baseline. 
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5.2.2 Statistical Analysis 
Clinical failure was defined as diagnosis with an AIDS defining opportunistic infec-
tion (OI) or CD4 T cell counts falling below 200 cells/mm3 . For patients who were 
diagnosed with an opportunistic infection prior to the start of the HAART regimen 
(N=51), clinical failure was defined as the time until the next opportunistic infection. 
A separate analysis was conducted with clinical failure defined as a diagnosis with an 
opportunistic infection only, regardless of CD4 T cell count, and yielded similar re-
sults (results not shown). Parameters associated with clinical failure were analyzed. 
The parameters included age, baseline CD4+ T cell count, baseline viral load, vi-
ral load over time, CD4 T cell count over time, initial virologic response to HAART, 
and history of opportunistic infections. In addition, pretreatment with antiretrovirals 
prior to the start of HAART was also considered. 
Data were analyzed using SAS version 6.11 (SAS Institute, Cary, NC). Survival 
time was measured as the date of therapy start until an AIDS defining event or censor-
ing t ime. Failure time was calculated by the Kaplan-Meier method. Comparisons of 
survival across subgroups were performed using the log-rank test and the Cox propor-
tional hazards model adjusted for left censoring to allow for staggered entry into the 
study. Associations among subgroups were examined with Kaplan-Meier plots and 
proportional hazards models, including partial likelihood ratio Chi square statistics. 
All p-values are two-sided. 
5.3 Results 
The characteristics of the 213 subjects are given in Table 1. To determine the time 
until clinical failure, survival analyses using Cox's proportional hazards model and 
Kaplan Meier were performed. Of the 213 subjects, 94 progressed to an AIDS defining 
endpoint. Figure 1 shows the Kaplan-Meier estimates of the proportion of subjects 
who did not experience clinical failure. The median time until clinical failure was 585 
days (95 percent confidence interval (CI): 505-647 days); see Table 2. 
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In the outpatient clinic, patients enter treatment at different stages of the disease. 
To test whether prior diagnosis with an opportunistic infection (OI) was a significant 
factor in clinical failure, both univariate and multivariate proportional hazards models 
were estimated. It was found that patients diagnosed with a prior opportunistic 
infection (OI) were more than five times more likely to experience clinical failure than 
patients who did not have an OI prior to starting HAART, RH=5.415 (p=O.OOOl). 
The patients were then stratified by opportunistic infection status prior to the start 
of HAART and Kaplan Meier curves were estimated. Patients with a previous history 
of an OI (N=51) had a median of 399 days until the onset of another OI; see Table 3. 
Patients who were not diagnosed with an opportunistic infection prior to the start of 
HAART had a median of 623 days until clinical failure; see Table 4. The difference 
between the two groups is significant at p=O.OOOl. Kaplan-Meier curves for patients 
with an OI prior to HAART and those without an OI prior to HAART are given in 
Figure 2. 
To assess the impact of antiretroviral pre-treatment before HAART, patients were 
stratified according to their previous experience with antiretrovirals. Thirty-seven 
antiretroviral naive patients were compared against 146 pre-treated patients. The 
relative risk for patients who were naive was significantly less than for patients who 
were pretreated, RH=0.417 (p= 0.039). HAART offers the best chance of long-term 
viral suppression for patients who start HAART antiretroviral naive. This result 
suggests that drug resistance may be playing a significant role in clinical failure of 
HAART. 
It has been shown that CD4+ T-cell counts are an important predictor of disease 
progression [36, 25, 40] . For purposes of analysis of CD4 T cell counts and the relation-
ship to clinical failure, it was necessary to redefine clinical failure as an opportunistic 
infection only. For this part of the analysis only, CD4 T count below 200 cells/mm3 
was not considered an AIDS defining event. In both univariate and multivariate anal-
yses, baseline CD4 T cell counts was an important predictor of disease progression 
for this patient group. Patients with higher baseline CD4 T cell counts had a de-
creased risk of progression, RH= 0.884 (p= O.OOl). Baseline CD4 T cell counts were 
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then stratified into clinically useful categories (less than 100, 100-199, 200-400, and 
greater than 400 cells/mm3). Kaplan Meier estimates of the proportion of patients 
who did not experience clinical failure were constructed for each stratum and given in 
Figure 3. Cox proportional hazards model was utilized to estimate the relative hazard 
of progression based on baseline CD4 T cell count. Subjects with CD4 T cell counts 
less than 100 cells/mm3 were nearly ten times more likely to progress than subjects 
whose CD4 T cell counts were above 400 cells/mm3 (RH=9.992, p=0.0001). Subjects 
with CD4 T cell counts between 100-199 cells/mm3 were more than four times and 
subjects with CD4 counts between 200 and 400 cellsjmm3 were three times more 
likely to progress to AIDS, RH=4.221 (p=0.001) and RH=2.991 (p=0.01) respec-
tively. These results suggest that baseline CD4 T cell counts have a significant effect 
on disease progression for patients on HAART and patients with higher baseline CD4 
T cell counts have a decreased risk of clinical failure. The fact that patients are ex-
periencing clinical failure despite HAART suggests that the increases in CD4 T cell 
counts due to HAART may be insufficient to prevent clinical failure. 
Other studies have found that baseline viral load is a significant predictor of disease 
progression [39, 36, 25]. In this study baseline viral load and age were not significant 
in predicting clinical failure, p>0.25. HAART has a dramatic effect on both HIV-1 
RNA levels (viral load) and CD4 T cell counts over time. We tested whether changes 
in these measures over time were significant. Changes in the levels of viral load 
and CD4 T cell counts, constructed as changes of the most recent test result from 
baseline, were very predictive. Increases in viral load from baseline were associated 
with increased risk of progression, RH=1.421 (p=0.0001); see Table 5. Changes in 
CD4 T cell counts from baseline that resulted in an increase were associated with a 
decrease in the risk of progression, RH=0.934 (p=0.01). 
Since HAART has the most rapid and dramatic effect on viral load, we tested 
whether the initial virological response was predictive of clinical failure. Virologic 
response was measured as the initial decrease in HIV-1 RNA levels from baseline 
after HAART implementation. It was found subjects with more dramatic responses 
(greater changes in HIV RNA levels after HAART initiation) had a decreased risk 
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of progression than those who had a more modest response, RH=0.722 (p=0.0016). 
Therefore, for each 1.0 log copies/ml decrease in HIV-1 RNA levels after HAART 
initiation, the hazard of clinical failure decreased by an estimated 27.8 percent. 
5.4 Discussion 
The use of HAART to treat HIV-infected patients has led to dramatically decreased 
morbidity and mortality. However, the failure of HAART to eradicate HIV [14, 15] 
leaves the patient vulnerable to the emergence of drug-resistant virus and resurgence 
of viral replication [12]. Wong et al. [12] found that the persistence of even low levels 
of detectable virus in the peripheral blood due to incomplete viral suppression reflects 
ongoing replication in the lymphoid system and the emergence of drug resistance. We 
performed a retrospective study to assess the clinical failure rate and the factors asso-
ciated with the risk of disease progression in a cohort of patients undergoing long-term 
HAART in an outpatient clinic. A high rate of clinical failure was found , with t he 
median failure rate of 585 days (95 percent confidence interval: 505-647 days) after 
the initiation of HAART. Patients who experienced an opportunistic infection before 
HAART implementation (N=51) had an increased risk of disease progression and a 
lower median time until clinical failure. This suggests that the initiation of antiretro-
viral treatment prior to rather than following the onset of an opportunistic infection 
is more effective in preventing or slowing down disease progression. Furthermore, pa-
tients who were naive to antiretroviral treatment prior to the start of HAART (N=37) 
had a decreased risk of clinical failure compared to patients who were antiretroviral 
experienced (p=0.039). It was found that patients with a greater initial virologic 
response to HAART, measured as initial decrease from baseline viral load at HAART 
implementation, had a decreased risk of progression compared to patients with a more 
modest response (p=0.0016). For each 1.0 log copies/ml decrease in HIV-1 RNA lev-
els after therapy start, the hazard of clinical failure decreased by an estimated 27.8 
percent. It was also found t hat patients with higher baseline CD4 T cell counts had 
a decreased risk of clinical failure compared to patients with lower baseline CD4 T 
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cell counts. Thus, these results suggest that HAART should be implemented early 
in HIV disease and that primary attempts with antiretroviral therapy offer the best 
chance for long-term viral suppression and increased t ime until AIDS. 
Our results indicate a high rate of clinical failure in an unselected cohort in the 
outpatient setting. Almost all of the patients experienced a rebound in viral load dur-
ing administration of HAART at which time salvage therapy regimens that included 
different combinations of antiretrovirals to which the patient was naive. Despite con-
tinued efforts to control virus replication through the introduction of different combi-
nations of drugs, most patients experienced clinical failure by progressing to an AIDS 
defining event. This disappointing result reflects the persistence of virus in infected 
patients and may be caused by the emergence of drug resistant virus, breakthrough 
of viral replication, or patient non-compliance to the treatment regimen. 
Patient noncompliance is an increasingly important issue when discussing long-
term treatment in an outpatient clinic. Patients who missed doses were not dropped 
from the study as long as the patient never fully stopped all antiretroviral medications. 
This intent-to-treat analysis yields results that mirrors more what is seen in the clinic 
as opposed to what is seen in the more controlled environment of a clinical trial. 
Levels of noncompliance, determined by the physician questioning the patient if they 
had taken all of their medications at each visit, were measured around 30 percent. 
Recent analysis has shown that noncompliance is a significant factor for clinical failure 
(p=0.01). 
Although many patients experienced clinical failure, only six died. This possibly 
suggests that HAART might have some therapeutic benefit that is not reflected in 
CD4 T-cell counts or HIV-1 RNA levels. This could also be a function of effective 
prophalaxis and treatment medication for opportunistic infections. Further follow up 
is necessary to test whether the decreases in mortality due to AIDS will continue to 
decline. However, the results suggest that the incidence of AIDS will increase as more 
and more patients continue to fail their HAART regimens. It seems that HAART 
was not "hard enough" [11] . Even for patients who are less experienced, the fact 
that HAART does not completely eradicate the virus leaves them susceptible to viral 
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mutation and breakthrough. New classes of drugs with different resistance profiles as 
well as strategies to boost the immune system are needed. Moreover, these results 
underscore the importance of the vaccine effort. 
5.5 Figures 
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Figure 5.1: Kaplan-Meier estimates of the proportion of subjects in whom the primary 
endpoint of clinical failure was not reached. The y axis shows the proportion of 
patients left in the sample who have not experienced clinical failure. The x axis is 
time on HAART in days. 
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Figure 5.2: Kaplan-Meier estimates of the proportion of subjects in whom the primary 
endpoint of clinical failure was not reached stratified by baseline CD4 T cell counts. 
T he y axis shows the proportion of patients left in the sample who have not experi-
enced clinical failure . The x axis is time on HAART in days. The black line represents 
the survival curve of patients with a baseline CD4 count of less than 100 cells/mm3 . 
The red line represents the survival curve of patients with 100-199 cells/mm3 . The 
green line shows the survival curve for patients with 200-399 cells/mm3 . The blue line 
shows the survival curve of patients with 400+ cells/mm3 . P <0.001 for the compar-
ison between subjects with greater than 400 cells/mm3 and subjects with less than 
100 cells/mm3 and 100-199 cells/mm3 • P=0.01 for the comparison of subjects with 
greater than 400 cells/mm3 and subjects with 200-399 cells/mm3 . 
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F igure 5.3: Kaplan-Meier estimates of the proportion of subjects in whom the primary 
endpoint of clinical failure was not reached. The y axis shows the proportion of 
patient s left in the sample who have not experienced clinical failure. The x axis is 
time on HAART in days. The solid line represents patients who did not have an 
opportunistic infection (OI) prior to the start of HAART. The dashed line represents 
patients who were diagnosed with an opportunistic infection before HAART was 
started. P = O.OOOl for the comparison between subjects who were diagnosed with an 
0 1 prior to HAART and subjects who did not experience an OI prior to the start of 
HAART. 
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5.6 Tables 
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Table 1. Characteristics of the 213 Patients at Base Line 
Sex- no.(%) 
Male 
Female 
Age in years - median (range) 
Clinical stage 
Asymptomatic (CDC stage A) 
Symptomatic (CDC stage B) 
Clinical AIDS (CDC stage C) 
CD4+ T cell count -cells/mm3 
Median (range) 
0-99 cells/mm3 - no. (%) 
100-199 cells/mm3 - no.(%) 
200-399 cells/mm3 - no. (%) 
400+ cells/mm3 -no. (%) 
Log HIV RNA -median copieslml (range) 
Antiretroviral experience 
Antiretroviral naTve - no. (%) 
Moderate - < 3 drugs· no. (%) 
Heavy - 3+ drugs -no. (%) 
195 (92%) 
18 (8%) 
41 (21-69) 
86 (40%) 
76 (36%) 
51 (24%) 
230(0-1011) 
43(20%) 
45 (22%) 
80 (36%) 
45 (22%) 
4.239 (1-5.8) 
37 (17%) 
114 (68%) 
32 (15%) 
Table 5.1: Characteristics of t he 213 patients at baseline 
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Table 2. Summary Statistics for Time until AIDS (In days) 
Quantile Point Estimate 95% Confidence Interval 
75% 
50% 
25% 
Mean 513.27 
585 
371 
709 
505 
310 
Standard Error 16.04 
--- refers to insufficeint data to estimate 
647 
426 
Table 5.2: Summary statistics for time until AIDS in days 
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Table 3. Summary Statistics for Patients with previous 01 (In days) 
Quantile 
75% 
50% 
25% 
Point Estimate 
639 
399 
185 
95% Confidence Interval 
486 
330 
130 
590 
490 
334 
Mean 394.54 Standard Error 29.93 
Table 5.3: Summary statistics for patients who experienced an opportunistic infection 
prior to the initiation of a HAART regimen 
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Table 4. Summary Statistics for Patients without Previous 01 (in days) 
Quantile 
75% 
50% 
25% 
Point Estimate 
nd 
623 
454 
95% Confidence Interval 
nd 
550 
366 
nd 
nd 
506 
Mean 552.99 Standard Error 17.94 
nd refers to insufficeint data to calculate 
Table 5.4: Summary statistics for patients who did not experience an opportunistic 
infection prior to the start of HAART 
Variable 
Age 
Change CD4 
Change HIV RNA 
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Table 5. Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald 
Estimates Error Chi Square 
-0.0167 
-0.0677 
0.3510 
0.0136 
0.0287 
0.0755 
1.464 
5.574 
21.642 
Pr > 
Chi Square 
0.2264 
0.0128 
0.0001 
Table 5.5: Analysis of Maximum Likelihood Estimates 
Risk 
Ratio 
0.984 
0.934 
1.421 
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Chapter 6 Limited Viral Suppression with 
Salvage Therapy After Combination Antiretroviral 
Therapy Failure in HIV-1 Infected Patients 
78 
Abstract 
We retrospectively evaluated 67 HIV-1 infected patients with clinical anti-retroviral 
resistance to assess the effectiveness of salvage therapy. Clinical resistance was de-
fined by fixed-elevated or rising plasma RNA PCR levels. All patients were failing 
combination anti-retroviral regimens which included at least one of the following pro-
tease inhibitors: saquinavir, indinavir, or ritonavir. Salvage therapy regimens that 
included the protease inhibitor nelfinavir plus two to four other antiretroviral medi-
cations were instituted. Viral load decreased on average by 0.55 log10 copies/ml and 
the decrease was sustained on average for five months before returning to baseline 
levels. Average CD4 counts rose by an average of 43 cells/mm3 however; this was 
not statistically significant. The median time until virologic failure was 87 days, with 
91.1 percent of the population failing by 225 days. The "hit early, hit hard" [11] ap-
proach may work well with those newly infected or treatment naive. However, these 
patients constitute a minority in most HIV practices. For patients who are experi-
enced with several antiretroviral agents or for whom response to primary treatment 
was sub-optimal, options for future treatment may be limited due to the presence of 
resistance-conferring mutations. Our results confirm that salvage therapy, even when 
there is at least one novel agent, is not effective in producing a durable virologic 
response in heavily treated patient populations. 
Keywords: Salvage therapy-HIV infection-Combination therapy failure-Drug resis-
tant HIV-1. 
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6.1 Introduction 
A growing number of patients with HIV-1 infection have fixed-elevated or rising 
plasma viral load levels despite highly-active anti-retroviral therapy (HAART) [42, 
43, 27, 44, 45]. In this circumstance, treatment regimens are usually modified (salvage 
therapy) in an effort to achieve better suppression of plasma viral load [46, 47]. Se-
quential monotherapy with nucleoside analogue reverse transcriptase (RT) inhibitors 
in the era prior to the introduction of protease inhibitors (PI) is recognized as one 
major cause of failure of combination RT-PI regimens; another is poor patient ad-
herence to these regimens [42, 27]. Both allow the evolution of resistance mutations 
which may diminish the effectiveness of salvage regimens [48, 12, 49]. It has been 
reported that in as many as 50 percent of cases, anti-retroviral therapy failed to con-
t rol viremia [50]. Prior failure of antiretroviral agents and cross-resistance can result 
in few viable option for subsequent treatment [51, 52, 53]. 
We retrospectively evaluated 67 patients who had clinical resistance to combi-
nation anti-retroviral therapy that included at least one of the other FDA-approved 
protease inhibitors (indinavir, saquinavir, or ritonavir) . At the time of salvage therapy 
implementation, all of the patients were nelfinavir naive. Preliminary data suggested 
that nelfinavir might have a distinct resistance pattern that might not overlap with 
other protease inhibitors [54, 55]. Salvage regimens were selected individuals to en-
sure a combination of antiretrovirals to which the patients were naive. In some cases, 
this was not possible so viral genotypic testing was performed to help guide the se-
lection of salvage drugs for these patients. All salvage regimens included nelfinavir 
plus two to four other antiretrovirals were initiated. After 86 days, roughly half of 
the population experienced virologic failure. Virologic failure is defined resurgence of 
HIV RNA in plasma. After 225 days, 91 percent of the population had failed. At the 
end of the follow up (approximately 640 days), 6/67 (8.9 percent) patients had un-
detectable viral loads. Overall, for the overwhelming majority of patients (61/67) we 
did not see a sustainable virologic response to salvage therapy after primary attempts 
of combination therapy failed. 
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6.2 Methods 
6.2.1 Study Population 
The data were constructed from a retrospective chart review of 67 HIV-1 infected 
patients in a primary HIV care office, who were failing combination anti-retroviral 
t herapy as indicated by fixed-elevated or rising plasma RNA viral load. Subjects 
gave consent under the condition that their anonymity be preserved. All subjects 
were nelfinavir naive, and initially received nelfinavir through an expanded access 
program. There were 60 men and 7 women. The average age was 43. The median 
viral load was 3.52log10 . The median CD4+T-lymphocyte count (CD4 count) was 254 
cellsfmm3 and the median CD8+T-lymphocyte count was 973 cells/mm3 • Fourteen 
patients had a prior AIDS defining illness. See Table 1. Most of the patients in 
our study were heavily pre-treated. Table 2 shows for each patient, antiretrovirals 
that were taken prior to the start of the salvage therapy regimen. 96 percent had 
prior AZT experience, 94 percent had prior 3TC experience, and 82 percent had 
prior indinavir experience. All patients were protease experienced. 19.4 percent 
were experienced with all 3 FDA approved protease inhibitors at the time (indinavir, 
saquinavir, and ritonavir) . Viral genotypic testing 1 was performed on 23 patients 
prior to t he initiation of t he salvage regimen. For the patients who were genotyped, 
antiretroviral drug histories were particularly complex or unreliable. The results of 
the genotypic testing were used to help guide the choice of salvage regimen. 
Individual salvage regimens were selected by review of patient's medication his-
tories, histories of adverse effects, and for those who were genotyped, t he resistance 
information [56, 57]. This was done to ensure that patients were given combinations 
of antiretrovirals to which the virus would be the most susceptible. Since all patients 
were naive to nelfinavir, it was chosen as one of the protease inhibitors for t he reg-
imens. In 28 out of 67 patients, nelfinavir was used in combination with another 
protease inhibitor. The most common salvage t herapy regimens were: D4T, 3T C, 
nelfinavir (18), two nucleoside analogues (AZT /3TC, D4T /3TC, or D4T /DDI) plus 
1 Genotypic analysis was performed at Specialty Labs in Santa Monica, CA. 
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nelfinavir and saquinavir (12), AZT, 3TC, nelfinavir (11), two nucleoside analogues 
plus nelfinavir and nevirapine (9) , two nucleoside analogs plus nelfinavir, saquinavir, 
and nevirapine (8), and one nucleoside analogue plus nelfinavir and saquinavir (6). 
The most common previous therapies that patients were failing at the time of the 
switch were: AZT, 3TC, indinavir (29 patients), D4T, 3TC, indinavir (15), and AZT, 
3TC, saquinavir, ritonavir (17). Follow-up time was approximately six months. 
6.2.2 Statistical Methods 
Virologic failure was defined viral resurgence. Data were analyzed using SAS version 
6.11 (SAS Institute, Cary, NC). Survival time was measured as date of start of salvage 
regimen until virologic failure. Failure time was calculated by the Kaplan-Meier 
method. A repeated measures analysis of variance with a teoplitz covariance matrix 
was used to analyze the different time points of viral load and CD4. Details of this 
procedure are in the appendix. 
6.3 Results 
The median time to virologic failure was 86 days. After 225 days roughly 91 percent 
of the patients experienced failure. See Figure 1 and Table 3. This dramatic failure 
rate underscores that fact primary attempts of combination therapy offer the best 
chance of controlling viral replication. Secondary, or salvage attempts, were not, for 
the vast majority of the population, able to produce a sustainable virologic response. 
The mean viral load in the baseline regimen was 3.52 log10 . After two months, 
viral load was 2.97log10 ; this represents a 0.55 log decrease in viral load. The decrease 
was significant at the p=0.047 level. At four months, viral load was 2.95 log10 . By 
6 months viral load 3.16 log10 . This was not significantly different from the baseline 
viral load (p=.1445). See Table 4. The plot of mean viral loads over time are presented 
in Figure 2. 
In the analysis of CD4 counts, we took the square root of CD4 counts to stabilize 
the variance [26]. The mean and standard errors of the square root of CD4 counts 
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are presented in Table 5. The numbers presented in the text have been transformed 
back to original counts. The mean CD4 count at baseline was 217 cells/mm3 (14. 71 
on the square root scale). After two months of salvage therapy, the average count 
rose to 244.0 cells/mm3 (15.6 on the square root scale). At the four month period 
average CD4 counts were 259.2 cells/mm3 (16.1 square root scale) . By six months, 
CD4 counts were 257.3 cells/mm3 (16.04 square root scale). The differences in CD4 
counts at all time periods were not significantly different from baseline CD4 (p> 0.26). 
Figure 3 shows the plot of CD4 counts over time on the square root scale. 
Only six patients (8.9 percent) had an undetectable viral load2 at 450 days, i.e., 
achieved the goal of HAART [58]. The overwhelming majority of patients, 61 , had 
an average decrease of 0.48 log which returned to baseline by six months. To better 
understand this result, we stratified the sample by indinavir failures (n=55) and 
ritonavir or saquinavir failures (indinavir naive)(n=12). We also examined whether 
the inclusion of the non-nucleoside reverse transcriptase inhibitor (nnrti), nevirapine, 
in those patients who were naive to this class of agents made a significant difference 
in the virologic response compared to the salvage regimens that did not contain an 
nnrti. Patients who had failed ritonavir or saquinavir and were indinavir naive had a 
1.27 log copies/ml drop from baseline viral load after initiating the salvage regimen 
(p=0.001) . After six months viral load levels returned to near baseline levels (p=0.14) . 
Two patients in this group had undetectable viral loads at the end of six months. The 
indinavir experienced group had a marginal decrease (.27log copies/ml) after salvage 
therapy implementation (p=0.04) and returned to baseline by six months (p=0.72). 
We also examined the subset of patients who received nevirapine as part of their 
salvage regimen. This group had a 0.94 log copies/ml drop from baseline viral load 
after initiating salvage therapy (p=.0015). This decrease was sustained until month 
6 when it was not significantly different from baseline (p=0.61). Two patients in this 
group had an undetectable viral load at the end of the study. Patient regimens that 
did not include nevirapine had a .45 log drop in viral load from baseline (p=.0051). 
Month six viral load was not significantly different from baseline (p=0.4159). 
2The lower limit of detection is 25 copies/ml. 
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Viral genotyping for HIV anti-retroviral drug-resistance was performed in 23 pa-
tients prior to the change in regimen. Genotypic analysis was performed only for 
patients with particularly complex drug histories. For these patients we found that 
91 percent of the viral isolates had the 215 mutation in the reverse transcriptase gene, 
which is the primary mutation for AZT [59, 60]. The 184 mutation, the principal 
mutation for conferring 3TC resistance [61 , 62, 63], was present in 73 percent of the 
isolates. In the patient isolates, 42 percent had mutations at codons 184, 210, and 
215 which correlate with in vitro resistance to AZT and 3TC. Fewer than 10 percent 
of patient isolates had mutations at codons 50 or 75, which is associate in vitro resis-
tance to D4T. In the protease gene, 68 percent of patient isolates had mutations at 
codon 90 which is a principal mutation for in vitro saquinavir resistance [64]. Mu-
tations at codon 82, a principal mutation for both indinavir and ritonavir [65, 66], 
was found in 36 percent of patient isolates. Mutation at codon 84, associated with 
multiple protease resistance [67, 44, 68, 52], was found in 36 percent of t he isolates. 
Figures 4 and 5 show the percentage of the patient isolates with each mutation in 
both the reverse transcriptase gene and the protease gene. On average, patients in 
this sub-population had 7 mutations in the reverse transcriptase gene and 4 mutations 
in the protease gene. 
A second ANOVA analysis was performed on the genotypic information to see 
which mutations were predictive of changes in log10 viral load. Patient isolates with 
mutations concurrently at protease codon 90 and RT codons 184, 210, and 215 had 
significantly higher log10 viral load at month six, p = 0.04. Patient isolates with 
mutations occurring simultaneously at protease codon 82, and RT codons 184, 210, 
and 215 had a significantly higher log10 viral load at month 6, p = 0.04. Patient 
isolates with mutations at both protease codons 82 and 84 had a higher viral load at 
month 6 than those who did not have these mutations, p = 0.009. 
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6.4 Discussion 
Overall we did not observe a sustained virologic response to salvage therapy in our pa-
tient group. Within 87 days, approximately half the population experienced virologic 
failure and within 225 days 91 percent had failed. Viral load remained undetectable 
in only 6/67 (8.1 percent) of patients. These patients had, on average, higher baseline 
CD4 counts and lower baseline viral loads than the rest of the population. See Table 
6. Suggesting that early intervention for salvage regimens might be beneficial. 
A sustained decrease in viral load greater than 0.5 log is generally considered 
biologically significant [69]. In our patient population, the decrease in average viral 
load was not sustained beyond six months, thus it is not clear whether or not these 
salvage regimens had any longterm effects on survival or quality of life. In other 
studies, decreases in viral load correlate with a significant benefit in survival. O'Brien 
[25] found that each threefold (0 .5 log) decrease in viral load was associated with a 
63 percent reduction in the relative hazard of progression (p = 0.02). Even more 
modest decreases of 0.3 log, if sustained, were associated with a 27 percent reduction 
in the relative hazard of progression [70]. The observed increase in CD4 counts in 
our patients might be expected to contribute some clinical benefit, but the level of 
increase was marginal, especially when compared to other studies such as the Swiss 
Cohort [27]. 
We believe that the failure to achieve sustained viral suppression in our population 
relates to extensive pre-treatment and to a high prevalence of resistance mutations 
among patient isolates. Indeed, the seven patients whose viral load remained unde-
tectable at six months were the least pre-treated. Almost half of the patient isolates 
that were genotyped had mutations associated with resistance to AZT and 3TC and 
greater than 36 percent of the isolates were cross-resistant to multiple protease in-
hibitors (due to the 82 and 84 mutation). This helps to explain the relatively modest 
effects of the salvage regimens on viral load. 
Winters et al. [49] recently reported that resistance patterns for saquinavir and 
nelfinavir overlap significantly. They reported that isolates that had reduced sus-
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ceptibilities in vitro to nelfinavir had either the 48 or 90 mutations. In our study, 
89 percent of the patient isolates had either the 48 or the 90 mutation. Thus prior 
protease inhibitor failure likely contributed to a suboptimal response to nelfinavir 
in the salvage combination regimens. Suboptimal response to nucleoside analogue 
RT inhibitors no doubt occurred as a result of prior combination therapy or serial 
monotherapy. This reinforces the fact that primary attempts at combination therapy 
have the most potential to induce remission of viremia. Secondary efforts (i.e., salvage 
therapy) will inevitably be at a disadvantage until new agents with non-overlapping 
resistance patterns become available. 
Plasma HIV RNA levels as well as CD4 counts are primary indicators that guide 
therapy modification. A patient's drug treatment history should be the major factor 
that directs the choice of a salvage regimen. Genotypic and phenotypic resistance 
testing may also be useful to help guide the choice of alternate salvage regimens 
for individual patient management [56]. For our patients, drug treatment history 
was the primary tool used to select the salvage regimen. For patients with complex 
treatment histories, genotypic testing was performed to help determine a feasible 
salvage regimen. Nelfinavir was chosen because it was a novel protease inhibitor 
whose preliminary resistance profile appeared promising for salvage therapy in that 
the pattern of resistance was different from other protease inhibitors [54, 55]. This, 
however, was not the case as was later demonstrated by Winters et al. [49] in vitro 
and confirmed by ours and others clinical experience. 
Genotypic and phenotypic assays may prove useful in selection of the most effective 
combination and sequences of antiretroviral agents [56]. Treatment with drugs that 
have differing resistance patterns would delay the emergence of cross-resistant viral 
strains [64] . Reserving agents for later use may preserve future treatment options. 
In retrospect, sequential treatment had a deleterious effect on the rate of virologic 
remission and limited the option of the patients. Our experience reinforces the need 
for caution and careful planning in the timing and selection of salvage regimens. A 
sustained result with nelfinavir containing regimens was precluded in part because of 
an unforeseen overlap in the resistance profile, prior protease inhibitor failure, and 
86 
lack of drugs in other classes to which the patients were naive. Utilization of nnrti's 
in the 17 patients who were nnrti-naive in all likelihood precludes further use of these 
agents in combination. This experience illustrates the dilemma faced by clinicians in 
utilizing antiretrovirals that are introduced sequentially. 
6.5 Appendix 
The statistical method we use tests whether the decrease in viral load and the increase 
in CD4 counts were significant. In our statistical model we control for effects due to 
time, therapy, and the interaction of therapy over time using fixed effect parameters. 
Our model specifies a random effect for individuals in different treatment groups 
to allow for the fact that individuals may have different responses to treatments. 
Because repeated observations such as viral load and CD4 counts in individuals tend 
to be correlated, we could not assume independence between the observations. We 
chose a more general framework for our variance-covariance matrix that estimated this 
covariance and incorporated it into the model. Failure to take this correlation into 
account can lead to biased standard errors and misleading results. We constructed a 
more complicated model to correctly estimate the standard errors. 
The model we specify is a two-factor analysis of covariance that distinguishes 
treatment and time: 
(6.1) 
where V i jk is the log10 vir ::~Kllo::~Kcl (or RC[ll::t.rP. root CD4 connt) for person ion therapy j 
at time k. O:j is a fixed effect for the therapy regimen j = 1, 2. f3k is a fixed effect for 
time period k = 0, ... , 3. In our study, j = 1 for the baseline regimen and j = 2 for 
the salvage therapy regimen. Time period, k = 0 denotes the baseline while k = 1, 2, 3 
denotes follow up periods measured at 2 month increments: 1 month, 3 months, and 
5 months. 
Allowing for the fact that individuals have differing responses to different treat-
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ments, we let 1rij be a random effect for the ith patient on treatment j. We assume 
that the 1rij are independent normally distributed N(O, u 2 ). The a{Jjk term is a fixed 
effect for the interaction of therapy and time. We specify that Eijk is a random error 
whose elements are not required to be independent. We assume that 7rij and Eijk 
are uncorrelated. We also assume (Eijk) has expectation 0 and denote its variance-
covariance matrix by R. Since the correlation of viral loads over time for a given 
individual is not constant, we used a general covariance matrix which allows for un-
equal correlations over time. The covariance matrix for individual i , ~Dhas Toeplitz 
structure with: 
(/2 0"1 (/2 0"3 
0"1 (/2 (/1 0"2 
~= 
(/2 (/1 (/2 0"1 
0"3 0"2 (/1 0"2 
where O"i is the correlation of the baseline observation with the ith observation. Thus 
R will be an MxM3 block diagonal matrix. 
Following Lindstrom and Bates [71] and Jennrich and Schluchter [72], equation 
(1) may be written: 
y = X/3 + Zv + c, (6.2) 
where y is a matrix of log viral loads or square root CD4 counts. Continuing, X is 
a matrix of indicator variables for the fixed effects and Z is a matrix of indicator 
variables for the random effects. f3 is a vector of unknown parameters and v is a 
random vector whose distribution is assumed multivariate normal with expectation 
zero and variance-covariance matrix G; i.e., v A.J N(O, G) . Following the assumptions 
above, G = u 2 I. Therefore, the covariance matrix of y, E, can be written as: 
E = R+ ZGZ'. (6.3) 
3In a balanced sample M = NxK, where N is the number of patients in t he sample (67) and K 
is the number of time periods (4). 
88 
It follows that y""' kEufzI~FK Since G equals (]'2 /, clearly ZGZ' = (]'2 / 011'. 
Thus ~D like R, will be block diagonal. It will also be symmetric about the diagonal 
and positive definite. 
Estimation of this model was performed by maximum likelihood using a ridge-
stabilized Newton-Raphson algorithm [73, 74] in SAS. We obtained estimates of 
the mean and standard errors of log viral loads and square root CD4 counts for all 
patients in the study population in the baseline, and the three subsequent follow-
up periods. The standard errors from the least squares means were computed by 
the method of Henderson [75]. To test the specification of our model after it was 
estimated, we performed a likelihood ratio test. The likelihood ratio test compares 
our mixed model covariance structure to a null model, where the null model is the 
standard linear model containing just the fixed effects and a simple residual variance 
of (]'2 I. The likelihood ratio test rejected the null model, (p = 0.0001), in favor of our 
specification. 
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6.6 Figures 
Figure 1 - Kaplan Meier curves of time until failure in days 
Figure 2 - Mean Log Viral Load Over Time 
Figure 3 - Mean Square Root CD4 Counts Over Time 
Figure 4- Percentage of Population with Reverse Transcriptase Mutations 
Figure 5- Percentage of the Population with Protease Mutations 
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Figure 6.1: Time until virologic failure after implementation of salvage therapy. The 
y axis shows the proportion of patients who have not failed. The x axis shows days 
until failure. 
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Mean Log Viral Load Over Time 
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Figure 6.2: Mean log viral load over time. 
92 
Mean Square Root CD4 Counts Over Time 
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Figure 6.3: Mean square root CD4 T cell counts over t ime. 
Q) 
0> 
ro 
....... 
c: 
Q) 
() 
L-
Q) 
a.. 
93 
Percentage of Population with 
Reverse Transcriptase Mutations 
1MM~----------------------------------------------~ 
90 -- --
80 -
70 ---
60 ---
50 ---
40 ---
30---
20 ---
10 --
································· ; ······························································ 
-+- Lt-- Lt-- -+- -+-
L{') "<;!- = L{') 0'> L{') 
~ ~ N N N N 
0 +----<=D----t-Dlil=-+-Dj:gD-D-+---D~D-D-D-+-~ 
.,...-- = "' L{') r-. = "<;!-
"<;!- L{') <.0 <.0 <.0 r-. r-. 
Codon 
=-
.,...--
"' ._,_-
co 
Figure 6.4: Percentage of the population with specified reverse transcriptase muta-
tions. 
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Percentage of the Population with Protease Mutations 
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Figure 6.5: Percentage of the population with specified protease mutations. 
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6.7 Tables 
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Table 1. Characteristics of patients at baseline 
Characteristic N 
Sex 
Male 
Female 
Mean age (yrs) 
Median CD4+ Teall cells/mm3 
Median COB+ Teall cells/mm3 
Prior opportunistic infection 
60 
7 
43 
254 
973 
14 
Table 6.1: Baseline characteristics of patients 
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Antivirals taken previous to salvage therapy 
Patient AZT DDI DDC D4T 3TC Indinavir Saquinavir Ritonavir 
1 X X X X X 
2 X X X X X 
3 X X X X X X X 
4 X X X X X 
5 X X X X 
6 X X X X X 
7 X X X 
8 X X X X X X X 
9 X X X X X X 
10 X X X X X 
11 X X X X 
12 X X X X 
13 X X X X 
14 X X X X 
15 X X X X X X X 
16 X X X X X 
17 X X X 
18 X X X X X 
19 X X X X X 
20 X X X X X X X X 
21 X X X 
22 X X X X 
23 X X X X X X 
24 X X X X 
25 X X X X X 
26 X X X X X 
27 X X X X 
28 X X X X X 
29 X X X X 
30 X X X X 
31 X X X X 
32 X X X X X X X 
33 X X X X X 
34 X X X X X 
35 X X X X 
36 X X X X 
Table 6.2: Antivirals taken previous to salvage therapy 
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Antivirals Taken Previous to Salvage Therapy (cont.) 
Patient AZT DDI DDC D4T 3TC Indinavir Saquinavir Ritonavir 
37 X X X X X 
38 X X X 
39 X X X X X 
40 X X X X X 
41 X X X X X X 
42 X X X X X X X 
43 X X X X X X 
44 X X X 
45 X X X 
46 X X X X X 
47 X X X X X X 
48 X X X X X 
49 X X X X 
50 X X X X 
51 X X X X 
52 X X X X 
53 X X X X 
54 X X X X 
55 X X X X X 
56 X X X X X X 
57 X X X X X X X 
58 X X X X X 
59 X X X X X 
60 X X X X X 
61 X X X X X 
62 X X X X X 
63 X X X X X 
64 X X X 
65 X X X X X X 
66 X X X X 
67 X X X X X X 
j Totals 64 23 8 48 63 55 38 23 
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Summary statistics for time until failure in days 
Quantile Point Estimate 95% Confidence Interval 
75% 206 118 427 
50% 87 77 118 
25% 66 54 77 
Mean: 153.765 Standard Error 17.819 
Table 6.3: Days until failure by quantile 
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Log Viral Load Over Time 
Time Mean Std. Err. Difference p-value 
Baseline (Time 0) 3.52 0.189 n/a n/a 
Salvage time 1 2.97 0.185 -0.55 0.05 
Salvage time 2 2.95 0.19 -0.57 0.1 
Salvage time 3 3.16 0.36 -0.36 0.14 
Table 6.4: Means and standard errors of log viral load over time 
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Square Root CD4+ Tcell Counts Over Time 
Time Mean Std. Err. Difference E-value 
Baseline (Time 0) 14.71 0.8385 n/a n/a 
Salvage time 1 15.6 0.8361 0.8969 0.4498 
Salvage time 2 16.1 0.8765 1.3608 0.2634 
Salva9e time 3 16.04 0.8854 1.3295 0.2771 
Table 6.5: Means and standard errors of CD4 T cell counts over time 
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Baseline Characteristics of Patients 1, 11, 35, 36,55, and 67 
Characteristic 
CD4 T-cells/mm3 
Viral load copies/ml 
Number of previous drugs 
Mean Median 
507.14 460 
131.57 94 
4.5 4 
Table 6.6: Baseline characteristics of the six patients who did not fail salvage therapy 
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Chapter 7 Outpatient Treatment Costs of 
HIV /AIDS in the Era of HAART 
104 
Abstract 
For the first time since the start of the epidemic, the incidence of morbidity and 
mortality due to HIV I AIDS has decreased [4]. This decrease is attributed to the 
widespread use of antiretrovirals taken in combination, often called HAART (highly 
active anti retroviral therapy) [10]. HAART, for the purposes of this study, is defined 
as a combination of three or more antiretroviral agents from at least two classes1 . 
Based on the projections of decreasing AIDS cases and subsequent reductions in 
hospitalizations, the costs attributed to HIV I AIDS are expected to decrease. The 
majority of the cost savings comes from the reductions in hospital visits. However, 
little is known about the long-term costs and effectiveness of HAART. This study 
looks at the costs of HIV I AIDS in the HAART era from 1995 to 1998 and compares 
it to the cost of therapy before HAART, 1988-1994 and to previous cost estimates in 
the pre-HAART era. The analysis shows that although HAART is more expensive 
to implement than the therapy available before HAART, there is a corresponding 
decrease in hospitalizations of HIV infected patients. Despite the decreased hospi-
talizations, the cost of treating patients with HAART is more expensive than the 
standard treatment patients were given previously. The incremental cost of HAART 
per year of life saved is estimated at $101,000 assuming HAART extends survival by 
four years. The incremental cost of HAART compares similarly with other treatments 
such as coronary artery bypass surgery and prostate-specific antigen screening. 
1 There are four classes of antiretrovirals, nucleoside, non-nucleoside, nucleotide, and protease 
inhibitors. 
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7.1 Introduction 
The use of combinations of antiretrovirals, often called Highly Active Anti Retro-
viral Therapy (HAART), to treat HIV-1 infected patients has dramatically reduced 
morbidity and given longer life in HIV infected patients [4, 10]. HAART is defined 
here as the use of three or more antiretroviral agents from two different classes used 
in combination to treat HIV-1 infection. Although HAART has offered hope, is it 
cost-effective? HAART is more expensive to implement than previous treatment. 
Antiretrovirals are very expensive; a monthly dose of a single protease inhibitor can 
cost up to $600 per month. Due to the frequency and severity of side effects, patients 
need to be monitored frequently for blood imbalances. Patients also need expensive 
lab tests such as viral load and viral genotypic testing to determine if the virus has 
mutated to a drug resistant strain. Viral mutations can frequently lead to drug resis-
tance and hamper efforts to control viral replication and subsequent disease progres-
sion. Frequent monitoring and laboratory testing is also expensive, viral load testing 
costs $200, viral genotyping costs $500 and viral phenotyping costs $1,000. Further, 
patients are also living longer and starting treatment earlier in the course of infection, 
leading to increased lifetime costs of treating HIV. However, patients on HAART have 
decreased incidence of AIDS defining opportunistic infections and decreased number 
of hospitalizations. Since hospitalizations and the AIDS stage comprise 58 percent 
of the lifetime costs of treating AIDS [3], prevention of these occurrences can have 
a significant effect on the cost of treatment. Recent reports have shown a dramatic 
decrease in the number of hospitalizations of patients on HAART. However, if the 
virus is not eradicated, then patients are still at risk of progression and this result 
may represent a short-term cost deferrment. 
A recent paper [76] has shown that patients on long-term HAART are beginning 
to fail, that is, patients are beginning to progress to an AIDS defining event such as 
an opportunistic infection. As more patients fail HAART, the incidence of AIDS will 
increase as will t he mortality rate due to HIV. As the rate of opportunistic infections 
increase, so will the number of hospitalizations. The increase in the hospitalization 
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rate will necessarily increase the cost of treating HIV infected patients and reduce the 
cost-savings gained by HAART. Since patients are living longer, starting treatment 
earlier in the course of t heir infection, and require more frequent monitoring and 
laboratory work, one would expect that t he cost of treating patients with HAART 
will be more expensive than the treatment given to patients before HAART. 
This paper looks at two groups of patients. The first group of patients were seen 
in an outpatient clinic from 1988-1994, the pre-HAART years. The second group of 
patients were seen at the same outpatient clinic during 1995-1998 and treated with 
HAART. With these two groups one can look at the cost patterns over time between 
treatment regimes. It was found that t he number of doctor visits has been steadily 
increasing from 1988-1998 with t he greatest increase from 1994 to 1995. The trend is 
similar with the number of laboratory tests such as CD4 T cell counts, complete blood 
counts and blood chemical screening. In the HAART regime, 1995-1998, the number 
of CD4 T cell count tests and viral load testing increased dramatically as would be 
expected because of the increased need for monitoring patients. The total number of 
hospitalizations increased from 1988 until1994. In 1995 there was a dramatic decrease 
in hospitalizations. This trend was sustained in 1998. To test whether the decrease 
in hospitalizations was enough to offset t he cost of increased monitoring, doctor visits 
and medication, the incremental cost per year of life saved was estimated for varying 
longevities. The total lifetime cost of treating HIV / AIDS was also estimated. It 
was found that as HAART increased survival times, the incremental cost per month 
gained decreased. If HAART had no effect on survival or on hospitalization, the 
incremental cost for HAART was $289,000, 95 percent confidence interval [$251,000-
$330,000]. However, if HAART increased survival by only six months, the cost per 
month gained was $51,000 [$44,000-$58,000]. If HAART increased survival by four 
years, the cost per month gained was $8,400 [$7,300-$9,500]. Assuming HAART 
extended life for four years, t he incremental cost of HAART per year of life saved was 
$101,000 [$88,000-$114,000]. 
The lifetime direct costs of treating an HIV infected patient before HAART was 
estimated at $132,000 [$123,000-$141,000] . The lifetime direct costs of treating HIV 
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with HAART ranged from $289,000 to $402,000 depending on the increased survival 
and the assumption that HAART has no sustained decrease in hospitalization. If 
HAART has a permanent decrease in hospitalizations of 30 percent, then the cost per 
year of life saved is only $96,000 [$82,000-$109,000]. 
7.2 Methods 
There are two distinct regimes in the treatment of HIV: HAART and pre-HAART. 
The pre-HAART regime extends from 1988-1994. This regime is defined from 1988 
until 1994 when there existed antiretroviral medication in the form of nucleoside re-
verse transcriptase inhibitors, prophalaxis medication for opportunistic infections but 
before protease inhibitors and combination therapy. Before HAART it was estimated 
that the average time from seroconversion (detection of HIV anti bodies) to AIDS 
was 10 years [6]. Patients progressed in a typical fashion with CD4 T cell counts 
decreasing in a monotonic pattern. Treatment in this era had only a transient effect 
on viral load and drug resistance was quickly established. The pre-HAART regime 
is substantially different from the HAART regimen whose therapy had a significant 
effect on CD4 T cell counts and viral load. Data on 210 patients who were seen in 
an outpatient clinic from 1988-1994 were collected by a retrospective chart review. 
Pat ients were chosen by a random sample of all patients in the HIV clinic. The only 
selection criteria was seropositivity. Data were collected on number of doctor visits, 
number of laboratory tests, number of hospitalizations, insurance status, costs and 
disease stage. 
Hellinger estimated the lifetime costs of treating an HIV infected person in 1992 
using the AIDS Cost and Services Utilization Study (ACSUS). This is a very detailed 
study on the various aspects of direct costs. The data collected from the outpatient 
clinic were compared to t he results of Hellinger's study. 
With the introduction of HAART in 1995, patients saw dramatic reductions in 
viral load (number of copies of HIV RNA in the peripheral blood) and substantial 
increases in CD4 T cell counts [33, 34, 35]. For the first t ime in the epidemic there 
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was hope. It has been hypothesized that combination treatment could suppress viral 
replication long enough to allow the immune system to recover or reconstitute [11]. 
By constructing a nonparametric density estimate of CD4 T cell counts from pa-
tients on HAART and comparing it to the CD4 distribution of uninfected patients, 
this hypothesis was tested. The resulting distribution is significantly below that of 
the uninfected population, suggesting that even with HAART, patients CD4 T cell 
counts do not increase to normal levels with HAART and thus patients are still im-
munocompromised [77]. It has also been hypothesized that utilizing antiretrovirals 
in combination would create a genetic barrier high enough so that HIV could not 
mutate around the drugs and cause resistance [11). Data from Ramirez 1998 [78) 
differs substantially from this hypothesis. Viral isolates that were genotyped found 
high levels of resistance in patients on HAART. In a subset of patients who had failed 
primary combination therapy, it was found that subsequent salvage therapy failed to 
suppress viral replication. This result reinforces the need for caution and strategic 
treatment in selecting antiretroviral agents. Although resistance is a major prob-
lem, patients on HAART have fewer hospitalizations and compared to the population 
before HAART was available. It was also found that patients who were naive, not 
experienced with antiretroviral therapy, had a significantly greater time unt il AIDS 
t han patients who were pre-treated. For patients who have been diagnosed with an 
opportunistic infection, naive status did not have a significant effect on time until the 
next opportunistic infection. This result suggests that patients should seek early and 
aggressive treatments. Since HAART is relatively new and HIV has a long latency 
period, it is too early to know the full effects of HAART on long-term survival for 
asymptomatic people. To fully address all of the cost issues, it would be necessary to 
have t he full survival distributions of all patients on HAART. In that way, one could 
know how much HAART increased the t ime until AIDS. Since the exact survival is 
not known, t he direct cost of treating patients with HAART is estimated for different 
levels of longevity. 
Data were collected on 258 patients in the same outpatient clinic who were on 
HAART from 1995-1998. Patients were selected by a random sample. For each 
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person, data were gathered on number of doctor visits, number of laboratory tests, 
number of CD4 T cell count tests, number of viral load tests, number of hospitaliza-
tions, insurance status, cost, and disease stage. 
Data for both groups were aggregated by year to assess the trends on a yearly 
basis. Average yearly costs for doctor visits and laboratory tests were estimated as 
well as average yearly costs for medication giving t he total outpatient cost per year. 
Total number of hospitalizations per year are also given. All dollars are in 1995 
dollars. 
7.3 Results 
7.3.1 Direct Costs of the Pre-HAART Era 
In 1992, Hellinger used self-reported charge data from the ACSUS (AIDS Cost and 
Service Utilization Study) to estimate the lifetime costs of HIV. He calculated the 
average monthly charges for patients in four stages of HIV infection. The stages were 
classified by CD4 T cell count and the presence of an AIDS defining opportunistic 
infection. Hellinger estimated that in the pre-HAART era, outpatient costs including 
drug costs were $4,771 per year. Hellinger estimated that patients spend 10.31 years 
before progressing to AIDS spending a $33,061 in outpatient costs and $50,174 in 
direct total costs. Direct total costs include inpatient costs and long-term care. Once 
diagnosed with AIDS, Hellinger estimated it was 25 months before the patient died. 
The outpatient cost for the AIDS stage per person was $16,125 and the direct total 
cost was $69,100. Combining the two total costs yields $119,274 as the lifetime cost of 
treating each HIV infected patient from seroconversion until death in the pre-HAART 
era. 
Data from the outpatient cohort from 1988-1994 are consistent with t he findings 
of Hellinger. Data was gathered on outpatient costs only. Data on hospitalization, 
home health care costs, and long term care were unavailable. In 1988 patient visited 
the doctor an average of 3.63 t imes. The rate was relatively stable throughout the 
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era but slightly increasing. By 1994, patients had an average of 4.90 doctor visits. 
In 1988 patients had an average of 9 laboratory tests performed, two of which were 
CD4 T cell count tests. Viral load testing was not widely available until 1995. By 
1994, patients had an average of 12.1 laboratory tests, three of which were CD4 T 
cell count tests. Doctor visits and laboratory test comprise the majority of outpatient 
costs. Table 7.1 lists the number of doctor visits and the number of laboratory tests 
performed each year. 
Outpatient costs were estimated based on charge data. Costs were estimated for 
each year in the pre-HAART era. It was estimated that each patient spent $1,098 
on average in 1988 on outpatient expenditures,. In 1994 patients spent, on average, 
$1,506.25 on outpatient care. Note that the numbers does not include the cost of 
medication. 
In the pre-HAART era nucleoside reverse transcriptase inhibitors were available to 
inhibit the replication of HIV. There also existed prophalactic medication for certain 
opportunistic infections. Medication costs were estimated by taking the average cost 
of the most frequently prescribed drug regimen. In the pre-HAART era the medi-
cation regimen included AZT (anti-HIV medicine), Bactrirn (Pneurnocystis Carinii 
pneumonia prophalactic, Difi ucan (thrush and fungal infections prophalaxis), Mari-
nol (combat side effects, stimulate appetite), and Acyclovir (anti-herpes drug). The 
average cost of this regimen was $295 [$249-$341] per month or $3,500 [$3,000-$4,100] 
per year. Adding drug costs with outpatient costs yields total outpatient direct costs 
per year and are given in Table 7.2. The average outpatient cost in the pre-HAART 
era was $1,400 [$1,200-$1,600] . When drugs were added to this cost, the average total 
outpatient cost was $4,900 [$4,200-$5,600]. 
Unfortunately, data on inpatient, horne health care and long-term care were un-
available for this outpatient group. Data were available on the total number of hos-
pitalizations. In 1988 there was 143 hospitalizations, yielding 1,269 hospital days. In 
1994 there were 275 hospitalizations, yielding 1,763 hospital days. The total number 
of hospitalization are given in Table 7.4. Since the hospital charts are unavailable, 
the cost for each of these hospitalizations are unknown. 
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Survival analysis with AIDS as the primary endpoint was performed on the clinical 
data with similar results to Hellinger. The median time from seroconversion until 
AIDS is 10.2 years. Median time from AIDS until death was 2.3 years. Hellinger 
estimates that patient takes 10.31 years from seroconversion until AIDS as defined 
by the presence of an opportunistic infection. Once a patient has an opportunistic 
infection, it takes 2.08 years until death. Outpatient cost estimates and the survival 
estimates from the outpatient data are consistent with that of Hellinger's estimates 
from ACSUS. Using Hellinger's estimates for inpatient, home health care, and long-
term care costs; lifetime average cost to treat an HIV-infected patient in the pre-
HAART era was $132,000 [$123,000-$141,000]. 
7.3.2 Direct Costs of HAART 
As HAART is relatively new, little is known about the long term cost and effective-
ness of HAART. Charge data were gathered on outpatient expenditures. Data on 
hospitalization, home health care, and long-term care cost were unavailable. Patients 
on HAART had an average of 6.5 doctor visits in 1995. This number increased to 9.67 
visits in 1996 and averaged 9.7 visits in 1998. The number of doctor visits per year 
are given in Table 7.1. The increase in doctor visits directly relates to the increased 
complexity of the HAART regimens compared with the t herapeutic regimens in the 
pre-HAART era. The severity and frequency of side effects necessitate increased mon-
itoring of patients. In 1995 the average number of laboratory tests performed was 
16.3 tests. This number rose to 27.17 tests in 1996 and increased to 27.30 tests in 
1998. The increase in testing is not only a function of side effects but also of resistance 
monitoring. Drug resistant HIV is a critical issue. Viral mutations that confer drug 
resistance can hamper efforts to control viremia and increase the likelihood of disease 
progression. Frequent monitoring and laboratory tests such as viral load testing and 
viral genotypic testing can detect emerging resistance. At the first sign of resistance 
the patient's antiretroviral regimen was modified to prevent high level resistance. In 
1995 patients had an average of 3.07 CD4 T cell count tests performed. In 1996 the 
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number rose to 4.89 tests and by 1998 patients had an average of 5.56 CD4 T cell 
count tests performed. Viral load testing became available in 1995 and became widely 
used in HIV treatment in 1996. In 1995 patients on HAART had an average of 1.27 
viral load tests performed. In 1996, patients had 5.53 tests performed and by 1998, 
patients had 5.97 viral load tests performed; see Table 7.3. Genotypic testing is very 
new and very expensive. Patients went from an average of 0.5 tests in 1997 to 1.41 
tests in 1998. 
Viral load testing costs $200, CD4 T cell count testing costs $165, and viral 
genotypic testing costs $500. The expense and frequency of these monitoring tests 
add substantially to the direct outpatient costs of treating patients with HAART. In 
1995 when HAART was first available, the average outpatient cost to treat a single 
patient was $2,111.25. This figure rose substantially in 1996, when viral load testing 
and HAART drugs were more widely available, to $3,875.35. By 1998, the average 
outpatient cost was $4,033.55. These figures do not include the price of medication. 
Antiretroviral medications are very expensive. These drugs are expensive to man-
ufacture and many are unstable and thus have a very short shelf life. Because of 
this and the fact that the research and development costs were enormous, it is not 
likely that the price for the drugs will come down substant ially in the near future. 
Average medications costs were estimated by taking t he average cost of the most 
prescribed drug regimen. In the HAART era t he most prescribed drug regimen was 
AZT, 3TC, Indinavir (all t hree anti-HIV drugs), Bactrim (P CP prophalaxis), Zithro-
max (to prevent Mycobacterium avium complex), Acyclovir (to treat herpes zoster), 
Diflucan (to prevent fungal infections) , Marinol (appetite stimulant), Zoloft (anti-
depressant), Oxandrin (to prevent wasting syndrome), and testoterone (to prevent 
wasting syndrome) . The average monthly cost of this regimen was $2,100 [$1,800-
$2,300]. Assuming no change in the regimen , the average yearly cost for medication 
was $24,600 [$21 ,500-$28,000]. 
Adding the cost of medication to the outpatient costs yield the total average 
outpatient costs for HAART. The average total outpatient cost for HAART was 
$28,100 [$24,000-$32,000]. These costs did not include hospitalizations, psychological 
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counseling, transportation costs, non-traditional or holistic medicine, or home health 
care costs. 
Use of these medications long-term will significantly increa..c;e cost. Assuming that 
t he drugs are effective and non-toxic for everyone, patients will incur more outpatient 
expenses in the form of outpatient visits and medication costs. These costs are sub-
stantially greater than that of the previous treatment regime. However, the greatest 
costs occur in the AIDS stage when hospitalizations are more likely. If HAART can 
prevent patients from needing to be hospitalized, then HAART could have a cost 
savings over the previous regime. When one looks at the total number of hospital-
izations per year in the HAART regime, one can see a substantial decrease. In 1995 
t here were 53 total hospitalizations. The number of hospitalizations remained rela-
t ively stable, and by 1998 there were 74 total hospitalizations. The average number 
of hospitalization in the HAART regime was 71, yielding an average of 439 hospitl 
days. See Table 7.4. Compared with 1,607 hospital days in the pre-HAART era 
suggests that the number of hospitalizations as well as the length of the hospital 
stay decreased under HAART. With the introduction of prophalactic medications 
for MAC (Mycobacterium aviium complex) and CMV (Cytomegalovirus), physicians 
were able to prevent some of the most costly opportunistic infections. Earlier studies 
have shown that PCP (Pneumocystis carinii pneumonia) prohpalaxis has decreased 
the incidence of PCP which was the most common opportunistic infection. As hospi-
talizations generally occur after t he onset of an opportunistic infection, and there has 
not been a substantial change in the treatment of opportunistic infections in the past 
7 years, there should not be a significant difference in inpatient treatment between 
regimes. However, as previous results have shown, HAART cannot fully prevent dis-
ease progression and opportunistic infections. Thus, the reductions in hospitalizations 
could be transient and, in fact, act as a cost delay. However, if HAART can prevent 
certain opportunistic infection that require lengthy hospital stays, there could be a 
cost-savings invloved. The analysis will take into account two scenarious, one where 
HAART only has a transient effect on inpatient and long-term costs and the second 
where HAART has a 30 percent reduction in inpatient costs due to decreased hospital 
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length. Thus under one regime, patients will spend an average of $70,000 on inpatient 
costs and the other $49,000, holding all else constant. 
Lifetime costs of treating patients on HAART depends on many factors; the ef-
ficacy of the drug at preventing disease progression, toxicity, long-term side effects, 
resistance, and patient compliance. Unfortunately, HAART is relatively new and the 
true long-term effects are unknown. Previous survival analysis [76] has shown that 
HAART cannot fully prevent disease progression. Other studies [14, 15] have shown 
that HIV is not eradicated therefore, patients are subject to viral rebound and disease 
progression. Given that patients will eventually fail but the exact failure time is not 
known, the cost per month of life gained can be calculated for various survival times. 
If HAART has no effect on prolonging life but decreases hospitalization costs by 
30 percent, then the total lifetime direct costs of treating an HIV infected patient 
is $400,000. If HAART does not decrease hospitalization costs and has no effect on 
survival, the lifetime cost is $421 ,000. If HAART is effective in prolonging life for 
four years, then the lifetime cost of treating that patient with HAART is $534,000. If 
HAART has a positive effect on survival but no effect on cost-savings and increases 
survival by 6 months, then the cost per month gained is $51,000. If HAART prolongs 
life by 12 months, then the cost per month gained is $27,000. If HAART increases 
survival by 48 months, the cost per month gained is only $8,400. The more HAART 
increases survival, the less the cost per month of life gained. Table 7.5 lists the lifetime 
direct costs of treating HIV /AIDS and the cost per month gained for various survival 
times. 
Because incremental costs are widely used to compare different medical interven-
tions, the incremental cost per year of life saved was estimated for HAART. If HAART 
extends life by four years, t hen the incremental cost per year of life is $101,000. The 
incremental cost of prostate-specific antigen screening is $113,000 per year saved and 
the incremental costs of coronary artery bypass surgery is also $113,000 per year 
saved. Thus HAART compares favorably to other common medical interventions. 
However, the number of HIV infected individuals is greater than candidates for other 
interventions. According to the latest Centers for Disease Control (CDC) estimates, 
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650,000 to 900,000 Americans are living with HIV and at least 40,000 new infections 
occur each year [4]. If every HIV-infected individual was put on HAART, the effects 
on the health care system could be staggering. 
HIV affect s a young population relative the the population who are candidates 
for coronary artery bypass surgery. These people are in their most productive work 
years. If HAART can keep these people working and productive memebers of society, 
the cost of HAART, in terms of society is actually much lower than $534,000. 
7.4 Discussion 
This paper has looked at treatment trends in HIV from the years 1988-1998. There are 
two distinct regimes in t his period; pre-HAART and HAART. Over time, costs have 
b een increasing. The increasing costs are due to the increased monitoring necessary 
to implement HAART as well as the costs of HAART itself. Although HAART is 
more expensive than t he pre-HAART t reatment, significant cost saving were seen due 
to the reductions in hospitalizations. Reductions in hospitalizations are due, for the 
most part, by the reduction in the incidence of AIDS defining opportunistic infections. 
Failure of HAART to eradicate t he virus leaves patient vulnerable to resistance 
and eventual resurgence of HIV [14, 15]. It is important to know that HIV is not over. 
As patients b egin to progress, the incidence of AIDS defining opportunistic infections 
and hospitalizations and cost will increase. 
To assess the impact of the cost of HAART on the health care system, it is 
necessary to look at the cost to treat all HIV infected patients. Before effective 
treatment many patients did not come in for testing or treatment. Thus, they did 
not affect the cost of treating HIV /AIDS until t hey became very sick. With HAART 
t here is an effective treatment that can prolong life if taken early enough. Now t here 
is an incentive for patients who were previously untreated to start taking HAART. 
This could increase the CDC figures of t he number of HIV infected people in t he 
United States. The more people seek treatment , the higher the total cost on the 
health care system. 
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As more patients go in Health Maintenance Organizations (HMO's), it will be 
interesting to see how they respond. HIV treatment will be along defined clinical 
guidelines and benefits given based on predicted costs. Managing costs in a disease 
that has so far been unmanageable remains a challenge to those in the HMO industry. 
HIV treatment is very complex and dynamic. The very nature of treatment has 
changed as new treatment and technologies become available. As has been shown 
earlier, even a lifetime capitation rate of $250,000 would be insufficient to care for an 
HIV infected individual on HAART. 
Unfortunately, there is insufficient data available to calculate exactly how long 
HAART delays disease progression. As HIV is at least a ten year disease, and HAART 
has only been available for four years, it is not possible to predict when the majority 
of patients on HAART will progress. Detailed data needs to be collected prospectively 
on patients on HAART. Data especially on newly infected individuals who start early 
and aggressive treatment is especially needed as t hese patients have the best chance of 
succeeding with HAART. Data needs to be collected on their antiretroviral treatment 
regimens, prior treatment regimens, side effects, viral load, CD4 T cell count, CDS 
T cell count evolut ion of viral genotype and phenotype, genotype of the individual, 
age, weight, and symptomology. In several years, one could know the true cost of 
HAART and the long-term efficacy of this regimen. T here is need for better drugs 
that are easier to take and less likely to confer cross-resistance. HAART as it stands 
is not enough. We are still far from a cure and policy makers need to be prepared for 
the eventuality of dramatically increased HIV /AIDS care costs. 
7.5 Tables 
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Average Number of Lab Tests and Doctor Visits 
Doctor Visits Lab Test (all) 
1988 3.63 1988 9.00 
1989 4.27 1989 10.10 
1990 4.81 1990 13.00 
1991 4.80 1991 13.00 
1992 4.60 1992 12.40 
1993 4.85 1993 12.00 
1994 4.90 1994 12.10 
1995 6.50 1995 16.30 
1996 9.67 1996 27.17 
1997 10.00 1997 26.52 
1998 9.70 1998 27.30 
Table 7.1: Average number of doctor visits and laboratory t est s per year 
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Average Outpatient Costs per Year 
Year Outpatient costs Drug Costs Total 
1988 $1,098.00 3543.24 $4,641.24 
1989 $1,248.25 3543.24 $4,791.49 
1990 $1,546.17 3543.24 $5,089.41 
1991 $1,545.00 3543.24 $5,088.24 
1992 $1,493.63 3543.24 $5,036.87 
1993 $1,506.25 3543.24 $5,049.49 
1994 $1,517.00 3543.24 $5,060.24 
1995 $2,1 11 .25 24620.04 $26,731.29 
1996 $3,875.35 24620.04 $28,495.39 
1997 $3,921.70 24620.04 $28,541.74 
1998 $4,033.55 24620.04 $28,653.59 
Table 7.2: Average outpatient costs, drug costs, and total cost per year 
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Number of Monitoring Tests in the HAART Era 
CD4 Count Test VIral Load tests 
1995 3.07 1995 1.27 
1996 4.89 1996 5.53 
1997 5.06 1997 5.62 
1998 5.56 1998 5.97 
Table 7.3: Number of monitoring laboratory tests per year during HAART 
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Total Number of Hospital Visits per Year 
1988 143 
1989 157 
1990 172 
1991 184 
1992 279 
1993 224 
1994 275 
1995 53 
1996 82 
1997 75 
1998 74 
Table 7.4: Total number of hospitalizations per year 
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Lifetime Direct Costs of Treating HIV/AIDS 
Total cost 95%CI cost/ month gained 95% Cl 
Old Regime $132,000 
HAART Regime-Decreased Hospitalizations 
0 month gain $400,000 [353,000-449,000] $268,000 [230,000-308,000] 
6 month gain $414,000 [365,000-466,000] $47,000 [40,000-54,200] 
12 month gain $429,000 [378,000-481,000] $24,750 [21 ,000-28,000] 
24 month gain $457,000 [402,000-513,000] $13,542 [1 2,000-16,000] 
36 month gain $485,000 [402,000-513,000] $9,806 [8,400-11 ,000] 
48 month gain $513,000 [451 ,000-577,000] $7,938 [6,800-9, 1 00] 
HAART Regime-No Decrease in Hospitalizations 
0 month gain $421,000 [374,000-470,000] $289,000 [251 ,000-330,000] 
6 month gain $435,000 [386,000-487,000] $50,500 [44,000-58,000] 
12 month gain $450,000 [399,000-502,000] $26,500 [23,000-30,000] 
24 month gain $478,000 [423,000-534,000] $14,417 [13,000-16,000] 
36 month gain $506,000 [447,000-566,000] $10,389 [9,000-12,000] 
48 month gain $534,000 [472,000-598,000] $8,375 [7,300-9,500] 
Table 7.5: Lifetime direct costs and cost per month gained of using HAART to treat 
HIV/ AIDS 
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